Document:

Exhibit 10.2

 

Portions of this document have been redacted
pursuant to a Request for Confidential Treatment filed with the Securities and Exchange Commission pursuant to Rule 24b-2 under
the Securities Exchange Act of 1934, as amended. Redacted portions are indicated with the notation “*”.

 

    	 

    	 

    

 

 

 

    	 

    	 

    

  

Contract Number: HHSN261201400048C

 

CONTRACT TABLE OF CONTENTS

 

	 	Page
	 	 
	PART I - THE SCHEDULE	5
	 	 	 
	 	SECCTION B - SUPPLIES OR SERVICES AND PRICES/COSTS	5
	 	 	 
	 	ARTICLE B.1. BRIEF DESCRIPTION OF SUPPLIES OR SERVICES	5
	 	ARTICLE B.2. ESTIMATED COST AND FIXED FEE	5
	 	ARTICLE B.3. ADVANCE UNDERSTANDINGS	5
	 	ARTICLE B.4. PROVISIONS APPLICABLE TO DIRECT COSTS	8
	 	 	 
	 	SECTION C - DESCRIPTION/SPECIFICATIONS/WORK STATEMENT	9
	 	 	 
	 	ARTICLE C.1. STATEMENT OF WORK	9
	 	ARTICLE C.2. REPORTING REQUIREMENTS	9
	 	ARTICLE C.3. INVENTION REPORTING REQUIREMENT	12
	 	 	 
	 	SECTION D - PACKAGING, MARKING AND SHIPPING	13
	 	 	 
	 	SECTION E - INSPECTION AND ACCEPTANCE	13
	 	 	 
	 	SECTION F - DELIVERIES OR PERFORMANCE	13
	 	 	 
	 	ARTICLE F.1. PERIOD OF PERFORMANCE	13
	 	ARTICLE F.2. DELIVERIES	14
	 	ARTICLE F.3. CLAUSES INCORPORATED BY REFERENCE, FAR 52.252-2 (FEBRUARY 1998)	15
	 	 	 
	 	SECTION G - CONTRACT ADMINISTRATION DATA	16
	 	 	 
	 	ARTICLE G.1. CONTRACTING OFFICER’S REPRESENTATIVE (COR)	16
	 	ARTICLE G.2. KEY PERSONNEL, HHSAR 352.242-70 (January 2006)	16
	 	ARTICLE G.3. INVOICE SUBMISSION/CONTRACT FINANCING REQUEST AND CONTRACT FINANCIAL REPORT	17
	 	ARTICLE G.4. PROVIDING ACCELERATED PAYMENT TO SMALL BUSINESS SUBCONTRACTORS, FAR 52.232-40 (December 2013)	19
	 	ARTICLE G.5. INDIRECT COST RATES	20
	 	ARTICLE G.6. GOVERNMENT PROPERTY	20
	 	ARTICLE G.7. POST AWARD EVALUATION OF CONTRACTOR PERFORMANCE	21
	 	 	 
	 	SECTION H - SPECIAL CONTRACT REQUIREMENTS	21

 

    	2

    	 

    

  

Contract Number: HHSN261201400048C

 

	 	ARTICLE H.1. PROTECTION OF HUMAN SUBJECTS, HHSAR 352.270-4(b) (January 2006)	21
	 	ARTICLE H.2. HUMAN SUBJECTS	22
	 	ARTICLE H.3. RESTRICTION ON USE OF HUMAN SUBJECTS, HHSAR 352.270-6 (January 2006)	22
	 	ARTICLE H.4. REQUIRED EDUCATION IN THE PROTECTION OF HUMAN RESEARCH PARTICIPANTS	23
	 	ARTICLE H.5. HUMAN MATERIALS	23
	 	ARTICLE H.6. HUMAN MATERIALS (ASSURANCE OF OHRP COMPLIANCE)	23
	 	ARTICLE H.7. NIH POLICY ON ENHANCING PUBLIC ACCESS TO ARCHIVED PUBLICATIONS RESULTING FROM NIH-FUNDED RESEARCH	24
	 	ARTICLE H.8. NEEDLE DISTRIBUTION	24
	 	ARTICLE H.9. ACKNOWLEDGEMENT OF FEDERAL FUNDING	24
	 	ARTICLE H.10. RESTRICTION ON ABORTIONS	25
	 	ARTICLE H.11. CONTINUED BAN ON FUNDING OF HUMAN EMBRYO RESEARCH	25
	 	ARTICLE H.12. DISSEMINATION OF FALSE OR DELIBERATELY MISLEADING INFORMATION	25
	 	ARTICLE H.15. LIMITATIONS ON SUBCONTRACTING - SBIR	25
	 	ARTICLE H.16. ELECTRONIC AND INFORMATION TECHNOLOGY ACCESSIBILITY, HHSAR 352.239-73(b) (January 2010)	25
	 	ARTICLE H.17. CONFIDENTIALITY OF INFORMATION	26
	 	ARTICLE H.18. INSTITUTIONAL RESPONSIBILITY REGARDING INVESTIGATOR FINANCIAL CONFLICTS OF INTEREST - PHASE II	27
	 	ARTICLE H.19. PUBLICATION AND PUBLICITY	30
	 	ARTICLE H.20. REPORTING MATTERS INVOLVING FRAUD, WASTE AND ABUSE	30
	 	ARTICLE H.21. YEAR 2000 COMPLIANCE	30
	 	 	 
	PART II - CONTRACT CLAUSES	31
	 	 	 
	 	SECTION I - CONTRACT CLAUSES	31
	 	 	 
	PART III - LIST OF DOCUMENTS, EXHIBITS AND OTHER ATTACHMENTS	36
	 	 	 
	 	SECTION J - LIST OF ATTACHMENTS	36
	 	 	 
	1.	Statement of Work	36
	 	 	 
	2.	Invoice/Financing Request and Contract Financial Reporting Instructions for NIH Cost- Reimbursement Type Contracts, NIH(RC)-4	36
	 	 	 
	3.	Disclosure of Lobbying Activities, SF-LLL	36
	 	 	 
	4.	Government Property - Schedule	36
	 	 	 

 

    	3

    	 

    

  

Contract Number: HHSN261201400048C

 

	5.	Report of Government Owned, Contractor Held Property	36
	 	 	 
	PART IV - REPRESENTATIONS AND INSTRUCTIONS	37
	 	 	 
	 	SECTION K - REPRESENTATIONS AND CERTIFICATIONS	37
	 	 	 
	1.	Annual Representations and Certifications	37
	 	 	 
	2.	Annual Representations and Certifications, FAR Clause 52.204-8	37
	 	 	 
	3.	Human Subjects Assurance Identification Number	37

 

    	4

    	 

    

  

Contract Number: HHSN261201400048C

 

PART I -
THE SCHEDULE

 

SECTION
B - SUPPLIES OR SERVICES AND PRICES/COSTS

 

ARTICLE
B.1. BRIEF DESCRIPTION OF SUPPLIES OR SERVICES

 

This contract will (1) development a prototype
analytical system incorporating Enumeral’s technology, including automation, software and data analysis and (2) test prototypes
on clinical samples in collaborating academic laboratories to demonstrate clinical utility and advantages over analytical current
techniques.

 

ARTICLE
B.2. ESTIMATED COST AND FIXED FEE

 

a.           The
estimated cost of this contract is $952,349.

 

b.           The
fixed fee for this contract is $47,618. The fixed fee shall be paid in installments based on the percentage of completion of work,
as determined by the Contracting Officer, and subject to the withholding provisions of the clauses ALLOWABLE COST AND PAYMENT and
FIXED FEE referenced in the General Clause Listing in Part II, ARTICLE I.1. of this contract.

 

c.           The
total estimated amount of the contract, represented by the sum of the estimated cost plus the fixed fee, is $999,967.

 

ARTICLE
B.3. ADVANCE UNDERSTANDINGS

 

Other provisions of this contract notwithstanding,
approval of the following items within the limits set forth is hereby granted without further authorization from the Contracting
Officer.

 

a.           Establishment
of Indirect Cost Rate

 

Fringe benefits costs are funded at a rate
of 17% in an amount not to exceed $28,755 and General and Administrative (G&A) costs are funded at a rate of 40% in an amount
not to exceed $272,099; however, the Contractor shall not bill or be reimbursed for indirect costs until such time as an indirect
cost proposal has been submitted to the cognizant office responsible for negotiating the indirect cost rates, unless a temporary
billing rate(s) has been included herein. Unless otherwise specified below, the indirect cost rate proposal shall be submitted
no later than three (3) months after the date of contract award.

 

The Contractor may bill fringe benefits at
a temporary billing rate of 17% of direct labor and may bill G&A at a temporary billing rate of 40% total direct costs; until
such time as indirect costs have been established, provided, that the Contractor’s indirect cost proposal is submitted to
the cognizant office responsible for negotiating indirect costs no later than December 16, 2014. If the indirect
cost proposal is not submitted within this time frame, any temporary indirect costs billed after this due date will be suspended
until such time as the indirect cost proposal is submitted.

 

    	5

    	 

    

  

Contract Number: HHSN261201400048C

 

The Government is not obligated to pay any
additional amount should the final indirect cost rates exceed the above ceiling. In the event that the final indirect cost rates
are less than these ceilings rates, the Government’s obligation shall be reduced to conform to the lower rate.

 

The Contractor shall complete all work in
accordance with the Statement of Work, terms and conditions of this contract.

 

b.           Subcontract

 

A cost-reimbursement type subcontract with
* for the installation and work with the prototype system and optimization of the process from the standpoint of end-users for
an amount not to exceed $71,778 for the period 9/16/14-9/15/16. A copy of the signed, executed subcontract shall be provided to
the Contracting Officer prior to performing work under this contract.

 

A cost-reimbursement type subcontract with
* for their participation in the evaluation of the prototype for an amount not to exceed $71,465 for the period 9/16/14-9/15/16.
A copy of the signed, executed subcontract shall be provided to the Contracting Officer prior to performing work under this contract.

 

c.           Contractor/Subcontractor
Travel

 

Expenditures for travel (transportation, lodging,
subsistence, and incidental expenses) incurred in the direct performance of this contract shall be unallowable without the prior
written approval of the Contracting Officer. No retroactive active approvals will be issued and no travel costs incurred without
prior Contracting Officer approval will be approved.

 

All travel requests shall be sent to both
the Contracting Officer’s Representative (COR) and the Contracting Officer within ninety (90) calendar days prior to the
planned start date of the travel. Once the request is received, the COR shall submit the required documentation to the appropriate
approving authority. Once it is determined that the request is approved or disapproved the COR will notify the Contracting Officer
so that they can issue written approval or disapproval of the travel request.

 

    	6

    	 

    

  

Contract Number: HHSN261201400048C

 

d.           Equipment:

 

The Contractor is hereby authorized to utilize
contract funds towards the purchase of the following equipment for an amount not to exceed * for the period 9/16/2014 through 9/15/2016.

 

	Item	 	Unit Price	 	Unit Quantity	 	Subtotal
	1. *	 	*	 	*	 	*
	2. *	 	*	 	*	 	*
	3. *	 	*	 	*	 	*
	Total Equipment Cost	 	 	 	 	 	*

 

***Note that Items 2 and 3 shall be leased; whereas, item
1 shall be purchased.

 

e.           Funding
Variance

 

The Contractor agrees to immediately notify
the Contracting Officer in writing if there is an anticipated overrun (any amount) or unexpended balance (greater than 10 percent)
of the amount allotted to the contract, and the reasons for the variance. Also refer to the requirements of the Limitation of Funds
and Limitation of Cost Clause in this contract.

 

f.            Site
Visit

 

At the discretion of the Government, a site
visit may be required during this contract. The Contractor will either be required to host the site visit in person or via teleconference.

 

g.           Consultants
Consultant fees to be paid to the following individuals:

  

	Name	 	Rate 

Per Day	 	Number of Hours	 	Total Cost 

Excluding Travel 

Not to Exceed
	*	 	*	 	*	 	*
	*	 	*	 	*	 	*
	*	 	*	 	*	 	*
	*	 	*	 	*	 	*
	Total	 	 	 	 	 	*

 

h.           Contract
Number Designation

 

On all correspondence submitted under this
contract, the Contractor agrees to clearly identify the two contract numbers that appear on the face page of the contract as follows:

 

Contract No. HHSN261201400048C

 

NCI Control No. N44CO201400048

 

    	7

    	 

    

  

Contract Number: HHSN261201400048C

 

ARTICLE
B.4.  PROVISIONS APPLICABLE TO DIRECT COSTS

 

a.           Items
Unallowable Unless Otherwise Provided

 

Notwithstanding the clauses, ALLOWABLE COST
AND PAYMENT, and FIXED FEE, incorporated in this contract, unless authorized in writing by the Contracting Officer, the costs of
the following items or activities shall be unallowable as direct costs:

 

1.          Conferences
and Meetings

 

2.          Food
for Meals, Light Refreshments, and Beverages

 

3.          Promotional
Items [includes, but is not limited to: clothing and commemorative items such as pens, mugs/cups, folders/folios, lanyards,
and conference bags that are sometimes provided to visitors, employees, grantees, or conference attendees.]

 

4.          Acquisition,
by purchase or lease, of any interest in real property;

 

5.          Special
rearrangement or alteration of facilities;

 

6.          Purchase
or lease of any item of general purpose office furniture or office equipment regardless of dollar value. (General purpose
equipment is defined as any items of personal property which are usable for purposes other than research, such as office equipment
and furnishings, pocket calculators, etc.);

 

7.          Travel
to attend general scientific meetings;

 

8.          Foreign
travel;

 

9.          Consultant
costs;

 

10.        Subcontracts;

 

11.        Patient
care costs;

 

12.        Accountable
Government Property (defined as non-expendable personal property with an acquisition cost of $1,000 or more) and “sensitive
items” (defined as items of personal property (supplies and equipment that are highly desirable and easily converted to personal
use), regardless of acquisition value.

 

13.        Printing
Costs (as defined in the Government Printing and Binding Regulations).

 

    	8

    	 

    

  

Contract Number: HHSN261201400048C

 

b.           Travel
Costs

 

1.          Domestic
Travel

 

Total expenditures for domestic travel (transportation,
lodging, subsistence, and incidental expenses) incurred in direct performance of this contract shall not exceed $7,091 without
the prior written approval of the Contracting Officer.

 

2.          The
Contractor shall invoice and be reimbursed for all travel costs in accordance with Federal Acquisition Regulations (FAR) 31.2 -
Contracts with Commercial Organizations, Subsection 31.205-46, Travel Costs.

 

SECTION
C - DESCRIPTION/SPECIFICATIONS/WORK STATEMENT

 

ARTICLE
C.1.  STATEMENT OF WORK

 

a.           Independently
and not as an agent of the Government, the Contractor shall furnish all the necessary services, qualified personnel, material,
equipment, and facilities, not otherwise provided by the Government as needed to perform the Statement of Work, dated 9/4/2014,
set forth in SECTION J-List of Attachments, attached hereto and made a part of this contract.

 

	Document Title	 	Date
	Statement of Work - Phase II	 	9/4/2014

 

ARTICLE
C.2. REPORTING REQUIREMENTS

 

All reports required herein shall be submitted
in an electronic format via email as attachments to the following designated NCI Branch Distribution Mailbox: Ncibranchcinvoices@mail.nih.gov

 

Each email submission shall contain only one
deliverable. If the attached file for the deliverable exceeds 50 MB, the Contractor shall divide the deliverable into files of
50 MB each. All deliverables shall be limited to five file attachments or less.

 

The subject line of the email shall read as
follows:

 

Deliverable_Contract Number_Vendor’s
Name_Deliverable Description_Due Date

 

All electronic reports submitted shall be
compliant with Section 508 of the Rehabilitation Act of 1973. Additional information about testing documents for Section 508 compliance,
including guidance and specific checklists, by application, can be found at: http://www.hhs.gov/web/508/index.html under
“Making Files Accessible.”

 

a.           Technical
Reports

 

In addition to those reports required by the
other terms of this contract, the Contractor shad prepare and submit the following reports in the manner stated below and in accordance
with the DELIVERIES Article in SECTION F of this contract:

 

    	9

    	 

    

  

Contract Number: HHSN261201400048C

 

[Note: Beginning May 25, 2008, the Contractor
shall include, in any technical progress report submitted, the applicable PubMed Central (PMC) or NIH Manuscript Submission reference
number when citing publications that arise from its NIH funded research.]

 

1.          Quarterly
Progress Report

 

a.           This
report shall include a description of the activities during the reporting period and the activities planned for the ensuing reporting
period. The first reporting period consists of the first full three months of performance including any fractional part of the
initial month. Thereafter, the reporting period shall consist of three full calendar months.

 

b.           The
first report shall be due January 10, 2015. Thereafter, reports shall be due on or before the 10th Calendar day following each
reporting period.

 

2.          Annual
Progress Report

 

This report shall include a summation of the
results of the entire contract work for the period covered. An annual report will not be required for the period when the Final
Report is due. A Quarterly Report shall not be submitted when an Annual Report is due.

 

The first report shall cover the period 09/16/2014
through 09/15/2015 of this contract and shall be due on October 15, 2015. Thereafter, reports shall be due on or before the 15th
Calendar day following the reporting period.

 

3.          Annual
Technical Progress Report for Clinical Research Study Populations

 

The Contractor shall submit information about
the inclusion of women and members of minority groups and their subpopulations for each study being performed under this contract.
The Contractor shall submit this information in the format indicated in the attachment entitled, “Inclusion Enrollment Report,”
which is set forth in SECTION J of this contract. The Contractor also shall use this format, modified to indicate that it is a
final report, for reporting purposes in the final report. In addition, the NIH Policy and Guidelines on the Inclusion of Women
and Minorities as Subjects in Clinical Research, Amended, October, 2001 applies. If this contract is for Phase III clinical trials,
see II.B of these guidelines. The Guidelines may be found at the following website:

 

http://grants.nih.gov/grants/funding/women_min/guidelines_amended_10_2001.htm

 

Include a description of the plans to conduct
analyses, as appropriate, by sex/gender and/or racial/ethnic groups in the clinical trial protocol as approved by the IRB, and
provide a description of the progress in the conduct of these analyses, as appropriate, in the annual progress report and the final
report. If the analysis reveals no subset differences, a brief statement to that effect, indicating the subsets analyzed, will
suffice. The Government strongly encourages inclusion of the results of subset analysis in all publication submissions. In the
final report, the Contractor shall include all final analyses of the data on sex/gender and race/ethnicity.

 

    	10

    	 

    

  

Contract Number: HHSN261201400048C

 

4.          Draft
and Final Report

 

This report shall consist of the work performed
and results obtained for the entire contract period of performance as stated in SECTION F of this contract. This report shall be
in sufficient detail to describe comprehensively the results achieved. The Final Report shall be submitted on or before the last
day of the contract performance period. An Annual report shall not be required for the period when the Final Report is due.

 

The Contractor shall provide the Contracting
Officer with an electronic copy of the Final Report in draft form (in accordance with the DELIVERIES Article in SECTION F of this
contract. The Contracting Officer’s Representative (COR) will review the draft report and provide the Contracting Officer
with comments within 15 Calendar days after receipt. The Final Report shall be corrected by the Contractor, if necessary and the
final version delivered as specified in the above paragraph.

 

5.          Summary
of Salient Results

 

The Contractor shall submit, with the Final
Report, a summary (not to exceed 200 words) of salient results achieved during the performance of the contract.

 

b.           Other
Reports/Deliverables

 

1.          Reporting
of Financial Conflict of Interest (FCOI) - Phase II

 

All reports and documentation required by
45 CFR Part 94, Responsible Prospective Contractors including, but not limited to, the New FCOI Report, Annual FCOI Report, Revised
FCOI Report, and the Mitigation Report, shall be submitted to the Contracting Officer in Electronic format. Thereafter, reports
shall be due in accordance with the regulatory compliance requirements in 45 CFR Part 94.

 

45 CFR Part 94 is available at: http://www.ecfr.gov/cgi-bin/text-idx?c=ecfr&SID=0af84ca649a74846f102aaf664da1623&rgn=div5&view=text&node=45:1.0.1.1.51&idno=45.
See Part 94.5, Management and reporting of financial conflicts of interest for complete information on reporting requirements.

 

(Reference subparagraph g. of the INSTITUTIONAL
RESPONSIBILITY REGARDING INVESTIGATOR FINANCIAL CONFLICTS OF INTEREST Article in SECTION H of this contract.)

 

2.          Section
508 Annual Report - PHASE II

 

The Contractor shall submit an annual Section
508 report in accordance with the schedule set forth in the ELECTRONIC AND INFORMATION TECHNOLOGY ACCESSIBILITY Article in SECTION
H of this contract. The Section 508 Report Template and Instructions for completing the report are available at: http://www.hhs.qov/web/508/contracting/technology/vendors.html
under “Vendor Information and Documents.”

 

    	11

    	 

    

  

Contract Number: HHSN261201400048C

 

3.          NIH
Small Business Innovation Research (SBIR) Program Life Cycle Certification

 

In accordance with the SBIR/STTR Reauthorization
Act of 2011, the Contractor shall complete and submit the NIH Small Business Innovation Research (SBIR) Life Cycle Certification
form, located in SECTION J of the contract, to the Contracting Officer. This certification is required to ensure the Contractor
is meeting the program’s requirements during the life cycle of the contract.

 

The Life Cycle Certification form shall be
submitted as follows:

 

		·	Phase II SBIR Contractors shall submit the Certification prior to receiving more than 50% of the total contract amount AND
prior to final payment or disbursement.

 

The Contracting Officer, may, at any time
after award request further clarifications and supporting documentation in order to assist in the verification of any information
provided by the Contractor.

 

For additional information, see NIH Policy
Notice NOT-OD-13-116, entitled, “New Program Certifications Required for SBIR and STTR Awards,” located at: http://grants.nih.gov/grants/guide/notice-files/NOT-OD-13-116.html.

 

ARTICLE
C.3. INVENTION REPORTING REQUIREMENT

 

All reports and documentation required by
FAR Clause 52.227-11, Patent Rights-Ownership by the Contractor including, but not limited to, the invention disclosure report,
the confirmatory license, and the Government support certification, shall be directed to the Division of Extramural Inventions
and Technology Resources (DEITR), OPERA, OER, NIH, 6705 Rockledge Drive, Suite 310, MSC 7980, Bethesda, Maryland 20892-7980 (Telephone:
301-435-1986). In addition, one copy of an annual utilization report, and a copy of the final invention statement, shall be submitted
to the Contracting Officer. The final invention statement (see FAR 27.303(b)(2)(ii)) shall be submitted to the Contracting Officer
on the completion date of the contract.

 

All reports shall be submitted in accordance
with the DELIVERIES Article in SECTION F of this contract. The final invention statement (see FAR 27.303(b)(2)(ii)) shall be submitted
on the expiration date of the contract. All reports shall be sent to the following address:

 

OPERA, OEH, NIH

6705 Rockledge Drive

Suite 310, MSC 7980

Bethesda, MD 20892-7980

 

If no invention is disclosed or no activity
has occurred on a previously disclosed invention during the applicable reporting period, a negative report shall be submitted to
the Contracting Officer at the email address specified in SECTION F.

 

    	12

    	 

    

  

Contract Number: HHSN261201400048C

 

To assist contractors in complying with invention
reporting requirements of the clause, the NIH has developed “Interagency Edison,” an electronic invention reporting
system. Use of Interagency Edison is encouraged as it streamlines the reporting process and greatly reduces paperwork. Access
to the system is through a secure interactive Web site to ensure that all information submitted is protected. Interagency Edison
and information relating to the capabilities of the system can be obtained from the Web (http://www.iedison.gov), or by
contacting the Extramural Inventions and Technology Resources Branch, OPERA, NIH.

 

SECTION
D - PACKAGING, MARKING AND SHIPPING

 

All deliverables required under this contract
shall be packaged, marked and shipped in accordance with Government specifications. At a minimum, all deliverables shall be marked
with the contract number and Contractor name. The Contractor shall guarantee that all required materials shall be delivered in
immediate usable and acceptable condition.

 

SECTION
E - INSPECTION AND ACCEPTANCE

 

a.           The
Contracting Officer or the duly authorized representative will perform inspection and acceptance of materials and services to be
provided.

 

b.           For
the purpose of this SECTION, the Contracting Officer’s Representative (COR) is the authorized representative of the Contracting
Officer.

 

c.           Inspection
and acceptance will be performed at:

 

NCI, SBIR Program, MSC 9706

9609 Medical Center Drive, 1W544

Rockville, MD 20850-9706

 

Acceptance may be presumed unless otherwise
indicated in writing by the Contracting Officer or the duly authorized representative within 30 days of receipt.

 

d.           This
contract incorporates the following clause by reference, with the same force and effect as if it were given in full text. Upon
request, the Contracting Officer will make its full text available.

 

FAR Clause 52.246-9, Inspection of Research and Development
(Short Form) (April 1984).

 

SECTION
F - DELIVERIES OR PERFORMANCE

 

ARTICLE
F.1. PERIOD OF PERFORMANCE

 

a.           The
period of performance of this contract shall be from 9/16/2014 through 9/15/2016.

 

    	13

    	 

    

  

Contract Number: HHSN261201400048C

 

ARTICLE
F.2. DELIVERIES

 

Satisfactory performance of the final contract
shall be deemed to occur upon performance of the work described in the Statement of Work Article in SECTION C of this contract
and upon delivery and acceptance by the Contracting Officer, or the duly authorized representative, of the following items in accordance
with the stated delivery schedule:

 

a.           The
items specified below as described in the REPORTING REQUIREMENTS Article in SECTION C of this contract will be required to be delivered
F.o.b. Destination as set forth in FAR 52.247-35, F.o.b. DESTINATION, WITHIN CONSIGNEES PREMISES (APRIL 1984), and in accordance
with and by the dates specified below:

 

	Item No.	 	Description	 	Delivery Schedule
	1.	 	Quarterly Progress Report	 	Quarterly, due within 15 calendar days after each reporting period.
	2.	 	Annual Progress Report	 	Annually, due each year after the start of Phase II.
	3.	 	Section 508 Annual Report	 	Annually, due each year after the start of Phase II.
	4.	 	Annual Technical Progress Report for Clinical Research Study Populations	 	Annually, due each year after the start of Phase II.
	5.	 	Financial Conflict of Interest (FCOI)	 	When applicable per 45 CFR Part 94.
	6.	 	Draft Final	 	14 Days Before Last Day of the Contract Performance Period.
	7.	 	Final Report	 	Due on or before the Phase II completion date.
	8.	 	Summary of Salient Results	 	Due on or before the completion of Phase II.
	9.	 	Protection of Human Subjects Assurance Identification/IRB Certification/Declaration of Exemption”, Form OMB No. 0990-0263	 	Prior to starting any work involving human subjects.
	10.	 	Annual Utilization Report	 	Due one year after the start of Phase II.
	11.	 	Final Invention Statement	 	Due on or before contract completion date.
	12.	 	Invention Disclosure Report	 	Due on or before contract completion date.
	13.	 	New or Revised Financial Conflict of Interest (FCOI) Report and Mitigation Report	 	Due as FCOI arises.

 

    	14

    	 

    

  

Contract Number: HHSN261201400048C

 

	Item No.	 	Description	 	Delivery Schedule
	14.	 	SBIR Program Life Cycle Certification - Phase II - Report 1	 	Due prior to receiving 50% of the total contract amount.
	15.	 	SBIR Program Life Cycle Certification - Phase II - Report 2	 	Due on or before Phase II completion date.
	16.	 	Federal Wide Assurance (FWA) (As applicable). - An approved FWA is effective for 5 years from issuance date.	 	Prior to starting any work involving human subjects.  (Renewal confirmation as required.)
	17.	 	Institutional Review Board (IRB) (As applicable) - An IRB registration is effective for 3 years after issuance.	 	Prior to starting any work involving human subjects.  (Renewal confirmation as required.)

  

b.           The
above items shall be addressed and emailed to ncibranchcinvoices@mail.nih.gov. The following addresses are provided for
general correspondence and other deliveries:

 

	Addressee	 	Deliverable Item No.	 	Quantity
	Mandie S. White, Contracting Officer

National Cancer Institute

Office of Acquisitions, Room 4036

Riverside Five, Suite 400

8490 Progress Drive

Frederick, MD 21701	 	1-17	 	
        One (1) electronic copy

        *

	 	 	 	 	 
	
        *, COR

        National Cancer Institute

        NCI SBIR & STTR Programs, Room 9609 Medical Center Drive,
        MSC 9705

        Bethesda, MD 20892-9705
	 	1-9	 	
        One (1) electronic copy

        *

	 	 	 	 	 
	
        OPERA, OEH, NIH

        6705 Rockledge Drive

        Suite 310, MSC 7980

        Bethesda, Maryland 20892-7980
	 	12	 	
        One (1) hard copy to OPERA;

        One (1) electronic copy

         

        *

 

ARTICLE
F.3. CLAUSES INCORPORATED BY REFERENCE, FAR 52.252-2 (FEBRUARY 1998)

 

This contract incorporates the following clause
by reference, with the same force and effect as if it were given in full text. Upon request, the Contracting Officer will make
its full text available. Also, the full text of a clause may be accessed electronically at this address: http:/A/vww.acquisition.gov/far.

 

    	15

    	 

    

  

Contract Number: HHSN261201400048C

 

FEDERAL ACQUISITION REGULATION (48 CFR CHAPTER 1) CLAUSE:

 

52.242-15, Stop WorkOrder, Alternate I (April 1984) is
applicable to Phase II of this contract.

 

SECTION
G - CONTRACT ADMINISTRATION DATA

 

ARTICLE
G.1. CONTRACTING OFFICER’S REPRESENTATIVE (COR)

 

The following Contracting Officer’s
Representative (COR) will represent the Government for the purpose of this contract:

 

*

 

The COR is responsible for: (1) monitoring
the Contractor’s technical progress, including the surveillance and assessment of performance and recommending to the Contracting
Officer changes in requirements; (2) interpreting the statement of work and any other technical performance requirements; (3) performing
technical evaluation as required; (4) performing technical inspections and acceptances required by this contract; and (5) assisting
in the resolution of technical problems encountered during performance.

 

The Contracting Officer is the only person
with authority to act as agent of the Government under this contract. Only the Contracting Officer has authority to: (1) direct
or negotiate any changes in the statement of work; (2) modify or extend the period of performance; (3) change the delivery schedule;
(4) authorize reimbursement to the Contractor for any costs incurred during the performance of this contract; (5) otherwise change
any terms and conditions of this contract; or (6) sign written licensing agreements. Any signed agreement shall be incorporated
by reference in Section K of the contract

 

The Government may unilaterally change its
COR designation.

 

ARTICLE
G.2. KEY PERSONNEL, HHSAR 352.242-70 (January 2006)

 

The key personnel specified in this contract
are considered to be essential to work performance. At least 30 days prior to diverting any of the specified individuals to other
programs or contracts (or as soon as possible, if an individual must be replaced, for example, as a result of leaving the employ
of the Contractor), the Contractor shall notify the Contracting Officer and shall submit comprehensive justification for the diversion
or replacement request (including proposed substitutions for key personnel) to permit evaluation by the Government of the impact
on performance under this contract. The Contractor shall not divert or otherwise replace any key personnel without the written
consent of the Contracting Officer. The Government may modify the contract to add or delete key personnel at the request of the
Contractor or Government.

 

(End of Clause)

 

The following individuals are considered to
be essential to the work being performed hereunder:

 

	Name	 	Title
	Arthur Tinkelenberg	 	Principal Investigator, President & CEO
	*	 	Senior Scientist
	*	 	Engineering Associate

 

    	16

    	 

    

 

Contract Number: HHSN261201400048C

 

ARTICLE
G.3. INVOICE SUBMISSION/CONTRACT FINANCING REQUEST AND CONTRACT FINANCIAL REPORT

 

a.           Invoice
Submission/Contract Financing Request and Contract Financial Reporting, NIH(RC)-4 for NIH Cost- Reimbursement Type Contracts are
attached and made part of this contract. The Contractor shall follow the attached instructions and submission procedures specified
below to meet the requirements of a “proper invoice” pursuant to FAR Subpart 32.9, Prompt Payment.

 

*

 

The Contractor shall submit an electronic
copy of the payment request to the approving official instead of a paper copy. The payment request shall be transmitted as an attachment
via e-mail to the address listed above in one of the following formats: MSWord, MS Excel, or Adobe Portable Document Format (PDF).
Only one payment request shall be submitted per e-mail and the subject line of the e-mail shall include the Contractor’s
name, contract number, and unique invoice number. [Note: The original payment request must still be submitted in hard copy
and mailed to the designated billing office to meet the requirements of a “proper invoice.”]

 

ncibranchcinvoices@mail.nih.gov

 

The Contractor shall submit an electronic
copy of the payment request to the Central Point of Distribution mailbox. The payment request shall be transmitted as an attachment
via e-mail to the address listed above in one of the following formats: MSWord, MS Excel, or Adobe Portable Document Format (PDF).
Only one payment request shall be submitted per e-mail and the subject line of the e-mail shall include the Contractor’s
name, contract number, and unique invoice number. [Note: The original payment request must still be submitted in hard copy
and mailed to the designated billing office to meet the requirements of a “proper invoice.”]

 

1.          Payment
requests shall be submitted to the offices identified below. Do not submit supporting documentation (e.g., receipts, time sheets,
vendor invoices, etc.) with your payment request unless specified elsewhere in the contract or requested by the Contracting Officer.

 

a.           The
original invoice shall be submitted to the following designated billing office:

 

National Institutes of Health

Office of Financial Management

Commercial Accounts

2115 East Jefferson Street, Room 4B-432, MSC 8500

Bethesda, MD 20892-8500

 

    	17

    	 

    

  

Contract Number: HHSN261201400048C

 

b.           One
courtesy copy of the original invoice shall be submitted electronically as follows:

 

1.          The
Contractor shall scan the original payment request (invoice) in Adobe Portable Document Format (PDF) along with the necessary supporting
documentation as one single attachment.

 

2.          Save
the single attachment (scanned invoice along with any supporting documentation) in the following format: YourVendorName_Invoice
number (e.g., if you are submitting Invoice 123456, save the single attachment as “Ash Stevens_Invoice 123456”) [Note:
Please do not use special characters such as (#, $, %,*, &, I) when saving your attachment. Only the underscore symbol (_)
is permitted.]

 

3.          Transmit
the saved single attachment via e-mail to the appropriate branch’s Central Point of Distribution. For the purpose of
this contract, the Central Point of Distribution is NCI OA Branch C - ncibranchcinvoices@mail.nih.gov. Only one payment
request shall be submitted per e-mail and the subject line of the e-mail shall include the Contract Number_ Contract Title_ Contractor’s
Name_ unique Invoice number (e.g, HHSN2612XXXXXC_Clinical Genetics Support_Ash Stevens_Invoice 12345) [Note: The original payment
request must still be submitted in hard copy and mailed to the designated billing office listed in subparagraph a, above, to meet
the requirements of a “proper invoice.” Also, The Contractor must certify on the payment request that the electronic
courtesy copy is a duplicate of the original invoice mailed to NIH’s Office of Financial Management.]

 

2.          In
addition to the requirements specified in FAR 32.905 for a proper invoice, the Contractor shall include the following information
on the face page of all payment requests:

 

a.           Name
of the Office of Acquisitions. The Office of Acquisitions for this contract is National Cancer Institute.

 

b.           Federal
Taxpayer Identification Number (TIN). If the Contractor does not have a valid TIN, it shall identify the Vendor Identification
Number (VIN) on the payment request. The VIN is the number that appears after the Contractor’s name on the face page of the
contract. [Note: A VIN is assigned to new contracts awarded on or after June 4, 2007, and any existing contract modified to
include the VIN number.] If the Contractor has neither a TIN, DUNS, or VIN, contact the Contracting Officer.

 

c.           DUNS
or DUNS+4 Number. The DUNS number must identify the Contractor’s name and address exactly as stated in the contract and as
registered in the Central Contractor Registration (CCR) database. If the Contractor does not have a valid DUNS number, it shall
identify the Vendor Identification Number (VIN) on the payment request. The VIN is the number that appears after the Contractor’s
name on the face page of the contract. [Note: A VIN is assigned to new contracts awarded on or after June 4, 2007, and any existing
contract modified to include the VIN number.]  If the Contractor has neither a TIN, DUNS, or VIN, contact the Contracting Officer.

 

d.           Invoice
Matching Option. This contract requires a two-way match.

 

    	18

    	 

    

  

Contract Number: HHSN261201400048C

 

e.           Unique
Invoice Number. Each payment request must be identified by a unique invoice number, which can only be used one time regardless
of the number of contracts or orders held by an organization.

 

f.            The
Contract Title is:

 

SBIR Phase II Topic 309: Deployment of Prototype System
for Detection of Multiple Analytes in Small Tissue Samples (9/16/14-9/15/16)

 

g.           Contract
Line Items as follows:

 

	Line Item #	 	Line Item Description
	1	 	SBIR Phase II Topic 309:  Deployment of Prototype System for Detection of Multiple Analytes in Small Tissue Samples (9/16/14-9/15/16)

 

a.           Inquiries
regarding payment of invoices shall be directed to the designated billing office, (301) 496-6452.

 

b.           The
Contractor shall include the following certification on every invoice for reimbursable costs incurred with Fiscal Year funds subject
to HHSAR Clause 352.231-70, Salary Rate Limitation in SECTION I of this contract. For billing purposes, certified invoices are
required for the billing period during which the applicable Fiscal Year funds were initially charged through the final billing
period utilizing the applicable Fiscal Year funds:

 

“I hereby certify that
the salaries charged in this invoice are in compliance with HHSAR Clause 352.231-70, Salary Rate Limitation in SECTION I of the
above referenced contract.”

 

ARTICLE
G.4. PROVIDING ACCELERATED PAYMENT TO SMALL BUSINESS SUBCONTRACTORS, FAR 52.232-40 (December 2013)

 

a.           Upon
receipt of accelerated payments from the Government, the Contractor shall make accelerated payments to its small business subcontractors
under this contract, to the maximum extent practicable and prior to when such payment is otherwise required under the applicable
contract or subcontract, after receipt of a proper invoice and all other required documentation from the small business subcontractor.

 

b.           The
acceleration of payments under this clause does not provide any new rights under the prompt Payment Act.

 

c.           Include
the substance of this clause, include this paragraph c, in all subcontracts with small business concerns, including subcontracts
with small business concerns for the acquisition of commercial items.

 

(End of Clause)

 

    	19

    	 

    

  

Contract Number: HHSN261201400048C

 

ARTICLE
G.5. INDIRECT COST RATES

 

In accordance with Federal Acquisition Regulation
(FAR) (48 CFR Chapter 1) Clause 52.216-7 (d)(2), Allowable Cost and Payment incorporated by reference in this contract in PART
II, SECTION I, the cognizant Contracting Officer representative responsible for negotiating provisional and/or final indirect cost
rates is identified as follows:

 

Director, Division of Financial Advisory Services

Office of Acquisition Management and Policy

National Institutes of Health

6011 EXECUTIVE BLVD, ROOM 549C, MSC-7663

BETHESDA MD 20892-7663

 

These rates are hereby incorporated without
further action of the Contracting Officer if the Contractor has an active rate agreement. If no rate agreement is in place, refer
to ARTICLE B.3 ADVANCED UNDERSTANDINGS for specific terms.

 

ARTICLE
G.6. GOVERNMENT PROPERTY

 

a.           In
addition to the requirements of the clause, GOVERNMENT PROPERTY, incorporated in SECTION I of this contract, the Contractor shall
comply with the provisions of HHS Publication, “HHS Contracting Guide for Contract of Government Property,” which is
incorporated into this contract by reference. This document can be accessed at: http://oamp.od.nih.gov/sites/default/files/appendix_g_hhs
contracting_guide.pdf. Among other issues, this publication provides a summary of the Contractor’s responsibilities regarding
purchasing authorizations and inventory and reporting requirements under the contract.

 

Requests for information regarding property
under this contract should be directed to the following office:

 

Division of Logistics Services, NIH

Property Management Branch

6011 Building, Suite 639

6011 EXECUTIVE BLVD MSC 7670

BETHESDA MD 20892-7670

nihcontractproperty@nih.gov

 

b.           Notwithstanding
the provisions outlined in the HHS Publication, “HHS Contracting Guide for Contract of Government Property,” which
is incorporated in this contract in paragraph a. above, the Contractor shall use the form entitled, “Report of Government
Owned, Contractor Held Property” for submitting summary reports required under this contract, as directed by the Contracting
Officer or his/her designee. This form is included as an attachment in SECTION J of this contract.

 

    	20

    	 

    

  

Contract Number: HHSN261201400048C

 

c.           Contractor-Acquired
Government Property - Schedule I-A

 

Pursuant to the clause, GOVERNMENT PROPERTY,
incorporated in this contract, the Contractor is hereby authorized to acquire the property listed in the attached Schedule I-A
for use in direct performance of the contract. Schedule I-A is included as an attachment in SECTION J of this contract.

 

ARTICLE
G.7. POST AWARD EVALUATION OF CONTRACTOR PERFORMANCE

 

a.           Contractor
Performance Evaluations

 

Interim and Final evaluations of Contractor
performance will be prepared on this contract in accordance with FAR Subpart 42.15. The Final performance evaluation will be prepared
at the time of completion of work. In addition to the Final evaluation, Interim evaluations will be prepared Annually as determined
by the Contracting Officer.

 

Interim and Final evaluations will be provided
to the Contractor as soon as practicable after completion of the evaluation. The Contractor will be permitted thirty days to review
the document and to submit additional information or a rebutting statement. If agreement cannot be reached between the parties,
the matter will be referred to an individual one level above the Contracting Officer, whose decision will be final.

 

Copies of the evaluations, Contractor responses,
and review comments, if any, will be retained as part of the contract file, and may be used to support future award decisions.

 

b.           Electronic
Access to Contractor Performance Evaluations

 

Contractors may access evaluations through
a secure Web site for review and comment at the following address:

 

http://www.cpars.gov

 

SECTION
H - SPECIAL CONTRACT REQUIREMENTS

 

ARTICLE
H.1. PROTECTION OF HUMAN SUBJECTS, HHSAR 352.270-4(b) (January 2006)

 

a.           The
Contractor agrees that the rights and welfare of human subjects involved in research under this contract shall be protected in
accordance with 45 CFR Part 46 and with the Contractor’s current Assurance of Compliance on file with the Office for Human
Research Protections (OHRP), Department of Health and Human Services. The Contractor further agrees to provide certification at
least annually that the Institutional Review Board has reviewed and approved the procedures, which involve human subjects in accordance
with 45 CFR Part 46 and the Assurance of Compliance.

 

b.           The
Contractor shall bear full responsibility for the performance of all work and services involving the use of human subjects under
this contract and shall ensure that work is conducted in a proper manner and as safely as is feasible. The parties hereto agree
that the Contractor retains the right to control and direct the performance of all work under this contract. The Contractor shall
not deem anything in this contract to constitute the Contractor or any subcontractor, agent or employee of the Contractor, or any
other person, organization, institution, or group of any kind whatsoever, as the agent or employee of the Government. The Contractor
agrees that it has entered into this contract and will discharge its obligations, duties, and undertakings and the work pursuant
thereto, whether requiring professional judgment or otherwise, as an independent contractor without imputing liability on the part
of the Government for the acts of the Contractor or its employees.

 

    	21

    	 

    

  

Contract Number: HHSN261201400048C

 

c.           If
at any time during the performance of this contract, the Contracting Officer determines, in consultation with OHRP that the Contractor
is not in compliance with any of the requirements and/or standards stated in paragraphs (a) and (b) above, the Contracting Officer
may immediately suspend, in whole or in part, work and further payments under this contract until the Contractor corrects the non
compliance. The Contracting Officer may communicate the notice of suspension by telephone with confirmation in writing. If the
Contractor fails to complete corrective action within the period of time designated in the Contracting Officer’s written
notice of suspension, the Contracting Officer may, after consultation with OHRP, terminate this contract in whole or in part, and
the Contractor’s name may be removed from the list of those contractors with approved Human Subject Assurances.

 

(End of clause)

 

ARTICLE
H.2. HUMAN SUBJECTS

 

Research involving human subjects shall not
be conducted under this contract until the protocol developed in Phase I has been approved by the National Cancer Institute, written
notice of such approval has been provided by the Contracting Officer, and the Contractor has provided to the Contracting Officer
a properly completed “Protection of Human Subjects Assurance Identification/IRB Certification/Declaration of Exemption”,
Form OMB No. 0990-0263 (formerly Optional Form 310) certifying IRB review and approval of the protocol. The human subject certification
can be met by submission of the Contractor’s self designated form, provided that it contains the information required
by the “Protection of Human Subjects Assurance Identification/IRB Certification/Declaration of Exemption”, Form OMB
No. 0990-0263 (formerly Optional Form 310).

 

When research involving Human Subjects will
take place at collaborating sites or other performance sites, the Contractor shall obtain, and keep on file, a properly completed
“Protection of Human Subjects Assurance Identification/IRB Certification/Declaration of Exemption”, Form OMB No. 0990-0263
(formerly Optional Form 310) certifying IRB review and approval of the research.

 

ARTICLE
H.3. RESTRICTION ON USE OF HUMAN SUBJECTS, HHSAR 352.270-6 (January 2006)

 

Pursuant to 45 CFR part 46, Protection of
Human Research Subjects, the Contractor shall not expend funds under this award for research involving human subjects or engage
in any human subjects research activity prior to the Contracting Officer’s receipt of a certification that the research has
been reviewed and approved by the Institutional Review Board (IRB) designated under the Contractor’s Federal-wide assurance
of compliance. This restriction applies to all collaborating sites, whether domestic or foreign, and subcontractors. The Contractor
must ensure compliance by collaborators and subcontractors.

 

    	22

    	 

    

  

Contract Number: HHSN261201400048C

 

(End of clause)

 

Prisoners shall not be enrolled in any HHS
research activities until all requirements of HHS Regulations at 45 CFR PART 46, Subpart C have been met. If a Research Subject
becomes a prisoner during the period of this contract, 45 CFR PART 46, Subpart C will apply to research involving that individual.

 

ARTICLE
H.4. REQUIRED EDUCATION IN THE PROTECTION OF HUMAN RESEARCH PARTICIPANTS

 

NIH policy requires education on the protection
of human subject participants for all investigators receiving NIH contract awards for research involving human subjects. For a
complete description of the NIH Policy announcement on required education in the protection of human subject participants, the
Contractor should access the NIH Guide for Grants and Contracts Announcement dated June 5, 2000 at the following website:

 

http://grants.nih.gov/grants/guide/notice-files/NOT-OD-00-039.html.

 

The information below is a summary of the
NIH Policy Announcement:

 

The Contractor shall maintain the following
information: (1) a list of the names and titles of the principal investigator and any other individuals working under the contract
who are responsible for the design and/or conduct of the research; (2) the title of the education program(s) in the protection
of human subjects that has been completed for each named personnel and; (3) a one sentence description of the educational program(s)
listed in (2) above. This requirement extends to investigators and all individuals responsible for the design and/or conduct of
the research who are working as subcontractors or consultants under the contract.

 

Prior to any substitution of the Principal
Investigator or any other individuals responsible for the design and/or conduct of the research under the contract, the Contractor
shall provide the following written information to the Contracting Officer: the title of the education program and a one sentence
description of the program that has been completed by the replacement.

 

ARTICLE
H.5. HUMAN MATERIALS

 

The acquisition and supply of all human specimen
material (including fetal material) used under this contract shall be obtained by the Contractor in full compliance with applicable
State and Local laws and the provisions of the Uniform Anatomical Gift Act in the United States, and no undue inducements, monetary
or otherwise, will be offered to any person to influence their donation of human material.

 

ARTICLE
H.6. HUMAN MATERIALS (ASSURANCE OF OHRP COMPLIANCE)

 

The acquisition and supply of all human specimen
material (including fetal material) used under this contract shall be obtained by the Contractor in full compliance with applicable
State and Local laws and the provisions of the Uniform Anatomical Gift Act in the United States, and no undue inducements, monetary
or otherwise, will be offered to any person to influence their donation of human material.

 

    	23

    	 

    

  

Contract Number: HHSN261201400048C

 

The Contractor shall provide written documentation
that all human materials obtained as a result of research involving human subjects conducted under this contract, by collaborating
sites, or by subcontractors identified under this contract, were obtained with prior approval by the Office for Human Research
Protections (OHRP) of an Assurance to comply with the requirements of 45 CFR 46 to protect human research subjects. This restriction
applies to all collaborating sites without OHRP-approved Assurances, whether domestic or foreign, and compliance must be ensured
by the Contractor.

 

Provision by the Contractor to the Contracting
Officer of a properly completed “Protection of Human Subjects Assurance Identification/IRB Certification/Declaration of Exemption”,
Form OMB No. 0990-0263(formerly Optional Form 310), certifying IRB review and approval of the protocol from which the human materials
were obtained constitutes the written documentation required. The human subject certification can be met by submission of a self
designated form, provided that it contains the information required by the “Protection of Human Subjects Assurance Identification/IRB
Certification/Declaration of Exemption”, Form OMB No. 0990-0263 (formerly Optional Form 310).

 

ARTICLE
H.7. NIH POLICY ON ENHANCING PUBLIC ACCESS TO ARCHIVED PUBLICATIONS RESULTING FROM NIH-FUNDED RESEARCH

 

NIH-funded investigators shall submit to the
NIH National Library of Medicine’s (NLM) PubMed Central (PMC) an electronic version of the author’s final manuscript,
upon acceptance for publication, resulting from research supported in whole or in part with direct costs from NIH. NIH defines
the author’s final manuscript as the final version accepted for journal publication, and includes all modifications from
the publishing peer review process. The PMC archive will preserve permanently these manuscripts for use by the public, health care
providers, educators, scientists, and NIH. The Policy directs electronic submissions to the NIH/NLM/PMC: http://www.pubmedcentral.nih.gov.

 

Additional information is available at http://grants.nih.gov/grants/Guide/notice-files/NOT-OD-08-033.html.

 

ARTICLE
H.8. NEEDLE DISTRIBUTION

 

The Contractor shall not use contract funds
to carry out any program of distributing sterile needles or syringes for the hypodermic injection of any illegal drug.

 

ARTICLE
H.9. ACKNOWLEDGEMENT OF FEDERAL FUNDING

 

The Contractor shall clearly state, when issuing
statements, press releases, requests for proposals, bid solicitations and other documents describing projects or programs funded
in whole or in part with Federal money: (1) the percentage of the total costs of the program or project which will be financed
with Federal money; (2) the dollar amount of Federal funds for the project or program; and (3) the percentage and dollar amount
of the total costs of the project or program that will be financed by nongovernmental sources.

 

    	24

    	 

    

  

Contract Number: HHSN261201400048C

 

ARTICLE
H.10. RESTRICTION ON ABORTIONS

 

The Contractor shall not use contract funds
for any abortion.

 

ARTICLE
H.11. CONTINUED BAN ON FUNDING OF HUMAN EMBRYO RESEARCH

 

The Contractor shall not use contract funds
for (1) the creation of a human embryo or embryos for research purposes; or (2) research in which a human embryo or embryos are
destroyed, discarded, or knowingly subjected to risk of injury or death greater than that allowed for research on fetuses in utero
under 45 CFR 46.204(b) and Section 498(b) of the Public Health Service Act (42 U.S.C. 289g(b)). The term “human embryo or
embryos” includes any organism, not protected as a human subject under 45 CFR 46 as of the date of the enactment of this
Act, that is derived by fertilization, parthenogenesis, cloning, or any other means from one or more human gametes or human diploid
cells.

 

Additionally, in accordance with a March 4,1997
Presidential Memorandum, Federal funds may not be used for cloning of human beings.

 

ARTICLE
H.12. DISSEMINATION OF FALSE OR DELIBERATELY MISLEADING INFORMATION

 

The Contractor shall not use contract funds
to disseminate information that is deliberately false or misleading.

 

ARTICLE
H.13. RESTRICTION ON PORNOGRAPHY ON COMPUTER NETWORKS

 

The Contractor shall not use contract funds
to maintain or establish a computer network unless such network blocks the viewing, downloading, and exchanging of pornography.

 

ARTICLE
H.14. GUN CONTROL

 

The Contractor shall not use contract funds
in whole or in part, to advocate or promote gun control.

 

ARTICLE
H.15. LIMITATIONS ON SUBCONTRACTING - SBIR

 

The Contractor shall perform a minimum of
one half of the contract effort [total contract costs less profit/fee] conducted under this contract. Any deviation from this requirement
must be approved in writing by the Contracting Officer.

 

ARTICLE
H.16. ELECTRONIC AND INFORMATION TECHNOLOGY ACCESSIBILITY, HHSAR 352.239-73(b) (January 2010)

 

a.           Pursuant
to Section 508 of the Rehabilitation Act of 1973 (29 U.S.C. 794d), as amended by the Workforce Investment Act of 1998, all electronic
and information technology (EIT) products and services developed, acquired, maintained, or used under this contract/order must
comply with the “Electronic and Information Technology Accessibility Provisions” set forth by the Architectural and
Transportation Barriers Compliance Board (also referred to as the “Access Board”) in 36 CFR part 1194. Information
about Section 508 provisions is available at http://www.section508.gov/. The complete text of Section 508 Final provisions
can be accessed at http://www.access-board.gov/guidelines-and-standards.

 

    	25

    	 

    

  

Contract Number: HHSN261201400048C

 

b.           The
Section 508 standards applicable to this contract/order are identified in the Statement of Work. The contractor must provide a
written Section 508 conformance certification due at the end of each contract/ order exceeding $100,000 when the contract/order
duration is one year or less, if it is determined by the Government that EIT products and services provided by the Contractor do
not conform to the described accessibility standards in the Product Assessment Template, remediation of the products or services
to the level of conformance specified in the Contractor’s Product Assessment Template will be the responsibility of the Contractor
at its own expense.

 

c.           In
the event of a modification(s) to this contract/order, which adds new EIT products or services or revises the type of, or specifications
for, products or services the Contractor is to provide, including EIT deliverables such as electronic documents and reports, the
Contracting Officer may require that the contractor submit a completed HHS Section 508 Product Assessment Template to assist the
Government in determining that the EIT products or services support Section 508 accessibility standards. Instructions for documenting
accessibility via the HHS Section 508 Product Assessment Template may be found on the HHS Web site (http://www.hhs.gov/web/508/contracting/technology/vendors.html).

 

[(End of HHSAR 352.239-73(b)]

 

d.           Prior
to the Contracting Officer exercising an option for a subsequent performance period/additional quantity or adding funding for a
subsequent performance period under this contract, as applicable, the Contractor must provide a Section 508 Annual Report to the
Contracting Officer and Project Officer. Unless otherwise directed by the Contracting Officer in writing, the Contractor shall
provide the cited report in accordance with the following schedule. Instructions for completing the report are available in the
Section 508 policy on the HHS Office on Disability Web site under the heading Vendor Information and Documents. The Contractor’s
failure to submit a timely and properly completed report may jeopardize the Contracting Officer’s exercising an option or
adding funding, as applicable.

 

Schedule for Contractor Submission of Section 508 Annual
Report: Annually

[End of HHSAR 352.239-73(c)]

 

ARTICLE
H.17. CONFIDENTIALITY OF INFORMATION

 

a.           Confidential
information, as used in this article, means information or data of a personal nature about an individual, or proprietary information
or data submitted by or pertaining to an institution or organization.

 

b.           The
Contracting Officer and the Contractor may, by mutual consent, identify elsewhere in this contract specific information and/or
categories of information which the Government will furnish to the Contractor or that the Contractor is expected to generate which
is confidential. Similarly, the Contracting Officer and the Contractor may, by mutual consent, identify such confidential information
from time to time during the performance of the contract. Failure to agree will be settled pursuant to the “Disputes”
clause.

 

    	26

    	 

    

  

Contract Number: HHSN261201400048C

 

c.           If
it is established elsewhere in this contract that information to be utilized under this contract, or a portion thereof, is subject
to the Privacy Act, the Contractor will follow the rules and procedures of disclosure set forth in the Privacy Act of 1974, 5 U.S.C.
552a, and implementing regulations and policies, with respect to systems of records determined to be subject to the Privacy Act.

 

d.           Confidential
information, as defined in paragraph (a) of this article, shall not be disclosed without the prior written consent of the individual,
institution, or organization.

 

e.           Whenever
the Contractor is uncertain with regard to the proper handling of material under the contract, or if the material in question is
subject to the Privacy Act or is confidential information subject to the provisions of this article, the Contractor should obtain
a written determination from the Contracting Officer prior to any release, disclosure, dissemination, or publication.

 

f.            Contracting
Officer determinations will reflect the result of internal coordination with appropriate program and legal officials.

 

g.           The
provisions of paragraph (d) of this article shall not apply to conflicting or overlapping provisions in other Federal, State or
local laws.

 

The following information is covered by
this article:

 

There will be no data or PII collection
under this project.

 

ARTICLE
H.18. INSTITUTIONAL RESPONSIBILITY REGARDING INVESTIGATOR FINANCIAL CONFLICTS OF INTEREST - PHASE II

 

The Institution (includes any contractor,
public or private, excluding a Federal agency) shall comply with the requirements of 45 CFR Part 94, Responsible Prospective Contractors,
which promotes objectivity in research by establishing standards to ensure that Investigators (defined as the project director
or principal Investigator and any other person, regardless of title or position, who is responsible for the design, conduct, or
reporting of research funded under NIH contracts, or proposed for such funding, which may include, for example, collaborators or
consultants) will not be biased by any Investigator financial conflicts of interest. 45 CFR Part 94 is available at the following
Web site: http://www.ecfr.gov/cgi-bin/text-idx? c=ecfr&SID=0af84ca649a74846f102aaf664da1623&rgn=div5&view=text&node=45:1.0.1.1.51&idno=45.
As required by 45 CFR Part 94, the Institution shall, at a minimum:

 

a.           Maintain
an up-to-date, written, enforceable policy on financial conflicts of interest that complies with 45 CFR Part 94, inform each Investigator
of the policy, the Investigator’s reporting responsibilities regarding disclosure of significant financial interests, and
the applicable regulation, and make such policy available via a publicly accessible Web site, or if none currently exist, available
to any requestor within five business days of a request. A significant financial interest means a financial interest consisting
of one or more of the following interests of the Investigator (and those of the Investigator’s spouse and dependent children)
that reasonably appears to be related to the Investigator’s institutional responsibilities:

 

    	27

    	 

    

 

Contract Number: HHSN261201400048C

 

1.          With
regard to any publicly traded entity, a significant financial interest exists if the value of any remuneration received from the
entity in the twelve months preceding the disclosure and the value of any equity interest in the entity as of the date of disclosure,
when aggregated, exceeds $5,000. Included are payments and equity interests;

 

2.          With
regard to any non-publicly traded entity, a significant financial interest exists if the value of any remuneration received from
the entity in the twelve months preceding the disclosure, when aggregated, exceeds $5,000, or when the Investigator (or the investigator’s
spouse or dependent children) holds any equity interest; or

 

3.          Intellectual
property rights and interests, upon receipt of income related to such rights and interest.

 

Significant financial interests do not include
the following:

 

1.          Income
from seminars, lectures, or teaching, and service on advisory or review panels for government agencies, Institutions of higher
education, academic teaching hospitals, medical centers, or research institutes with an Institution of higher learning; and

 

2.          Income
from investment vehicles, such as mutual funds and retirement accounts, as long as the Investigator does not directly control the
investment decisions made in these vehicles.

 

b.           Require
each Investigator to complete training regarding the Institution’s financial conflicts of interest policy prior to engaging
in research related to any NIH-funded contract and at least every four years. The Institution must take reasonable steps [see Part
94.4(c)] to ensure that investigators working as collaborators, consultants or subcontractors comply with the regulations.

 

c.           Designate
an official(s) to solicit and review disclosures of significant financial interests from each Investigator who is planning to participate
in, or is participating in, the NIH-funded research.

 

d.           Require
that each Investigator who is planning to participate in the NIH-funded research disclose to the Institution’s designated
official(s) the Investigator’s significant financial interest (and those of the Investigator’s spouse and dependent
children) no later than the date of submission of the Institution’s proposal for NIH-funded research. Require that each Investigator
who is participating in the NIH-funded research to submit an updated disclosure of significant financial interests at least annually,
in accordance with the specific time period prescribed by the Institution during the period of the award as well as within thirty
days of discovering or acquiring a new significant financial interest.

 

    	28

    	 

    

  

Contract Number: HHSN261201400048C

 

e.           Provide
guidelines consistent with the regulations for the designated official(s) to determine whether an Investigator’s significant
financial interest is related to NIH-funded research and, if so related, whether the significant financial interest is a financial
conflict of interest. An Investigator’s significant financial interest is related to NIH-funded research when the Institution,
thorough its designated official(s), reasonably determines that the significant financial interest: Could be affected by the NIH-funded
research; or is in an entity whose financial interest could be affected by the research. A financial conflict of interest exists
when the Institution, through its designated official(s), reasonably determines that the significant financial interest could directly
and significantly affect the design, conduct, or reporting of the NIH-funded research.

 

f.            Take
such actions as necessary to manage financial conflicts of interest, including any financial conflicts of a subcontractor Investigator.
Management of an identified financial conflict of interest requires development and implementation of a management plan and, if
necessary, a retrospective review and mitigation report pursuant to Part 94.5(a).

 

g.           Provide
initial and ongoing FCOI reports to the Contracting Officer pursuant to Part 94.5(b).

 

h.           Maintain
records relating to all Investigator disclosures of financial interests and the Institution’s review of, and response to,
such disclosures, and all actions under the Institution’s policy or retrospective review, if applicable, for at least 3 years
from the date of final payment or, where applicable, for the other time periods specified in 48 CFR Part 4, subpart 4.7, Contract
Records Retention.

 

i.            Establish
adequate enforcement mechanisms and provide for employee sanctions or other administrative actions to ensure Investigator compliance
as appropriate.

 

j.            Complete
the certification in Section K - Representations, Certifications, and Other Statements of Offerors titled “Certification
of Institutional Policy on Financial Conflicts of interest”.

 

If the failure of an Institution to comply
with an Institution’s financial conflicts of interest policy or a financial conflict of interest management plan appears
to have biased the design, conduct, or reporting of the NIH-funded research, the Institution must promptly notify the Contracting
Officer of the corrective action taken or to be taken. The Contracting Officer will consider the situation and, as necessary, take
appropriate action or refer the matter to the Institution for further action, which may include directions to the Institution on
how to maintain appropriate objectivity in the NIH-funded research project.

 

The Contracting Officer and/or HHS may inquire
at any time before, during, or after award into any Investigator disclosure of financial interests, and the Institution’s
review of, and response to, such disclosure, regardless of whether the disclosure resulted in the Institution’s determination
of a financial conflict of interests. The Contracting Officer may require submission of the records or review them on site. On
the basis of this review of records or other information that may be available, the Contracting Officer may decide that a particular
financial conflict of interest will bias the objectivity of the NIH-funded research to such an extent that further corrective action
is needed or that the Institution has not managed the financial conflict of interest in accordance with Part 94.6(b). The issuance
of a Stop Work Order by the Contracting Officer may be necessary until the matter is resolved.

 

    	29

    	 

    

  

Contract Number: HHSN261201400048C

 

If the Contracting Officer determines that
NIH-funded clinical research, whose purpose is to evaluate the safety or effectiveness of a drug, medical device, or treatment,
has been designed, conducted, or reported by an Investigator with a financial conflict of interest that was not managed or reported
by the Institution, the Institution shall require the Investigator involved to disclose the financial conflict of interest in each
public presentation of the results of the research and to request an addendum to previously published presentations.

 

ARTICLE
H.19. PUBLICATION AND PUBLICITY

 

In addition to the requirements set forth
in HHSAR Clause 352.227-70, Publications and Publicity incorporated by reference in SECTION I of this contract, the Contractor
shall acknowledge the support of the National Institutes of Health whenever publicizing the work under this contract in any media
by including an acknowledgment substantially as follows:

 

“This project has been
funded in whole or in part with Federal funds from the National Cancer Institute, National Institutes of Health, Department of
Health and Human Services, under Contract No. HHSN261201400048C”

 

ARTICLE
H.20. REPORTING MATTERS INVOLVING FRAUD, WASTE AND ABUSE

 

Anyone who becomes aware of the existence
or apparent existence of fraud, waste and abuse in NIH funded programs is encouraged to report such matters to the HHS Inspector
General’s Office in writing or on the Inspector General’s Hotline. The toll free number is 1-800-HHS-TIPS (1-800-447-8477).
All telephone calls will be handled confidentially. The website to file a complaint on-line is: http://oig.hhs.gov/fraud/hotline/
and the mailing address is:

 

US Department of Health and Human Services

Office of Inspector General

ATTN: OIG HOTLINE OPERATIONS

P.O. Box 23489

Washington, D.C. 20026

 

ARTICLE
H.21. YEAR 2000 COMPLIANCE

 

In accordance with FAR 39.106, Information
Technology acquired under this contract must be Year 2000 compliant as set forth in the following clause(s):

 

1.          Service
Involving the Use of Information Technology YEAR 2000 COMPLIANCE—SERVICE INVOLVING THE USE OF INFORMATION TECHNOLOGY

 

The Contractor agrees that each item of hardware,
software, and firmware used under this contract shall be able to accurately process date data (including, but not limited to, calculating,
comparing and sequencing) from, into and between the twentieth and twenty-first centuries and the Year 1999 and the Year 2000 and
leap year calculations.

 

(End of Clause)

 

    	30

    	 

    

  

Contract Number: HHSN261201400048C

 

PART II - CONTRACT CLAUSES

 

SECTION
I - CONTRACT CLAUSES

 

ARTICLE
I.1. GENERAL CLAUSES FOR A COST-REIMBURSEMENT SBIR PHASE II CONTRACT

 

This contract incorporates the following
clauses by reference, with the same force and effect as if they were given in full text. Upon request, the Contracting Officer
will make their full text available. Also, the full text of a clause may be accessed electronically as follows: FAR Clauses at:
http://www.acquisition.gov/far/. HHSAR Clauses at: http:// www.hhs. gov/policies/hhsar/subpart352.html.

 

		a.	FEDERAL ACQUISITION REGULATION (FAR) (48 CFR CHAPTER 1) CLAUSES:

 

	FAR

CLAUSE NO.	 	DATE	 	TITLE
	52.202-1	 	Nov 2013	 	Definitions (Over the Simplified Acquisition Threshold)
	52.203-3	 	Apr 1984	 	Gratuities (Over the Simplified Acquisition Threshold)
	52.203-5	 	May 2014	 	Covenant Against Contingent Fees (Over the Simplified Acquisition Threshold)
	52.203-6	 	Sep 2006	 	Restrictions on Subcontractor Sales to the Government (Over the Simplified Acquisition Threshold)
	52.203-7	 	May 2014	 	Anti-Kickback Procedures (Over the Simplified Acquisition Threshold)
	52.203-8	 	May 2014	 	Cancellation, Rescission, and Recovery of Funds for Illegal or Improper Activity (Over the Simplified Acquisition Threshold)
	52.203-10	 	May 2014	 	Price or Fee Adjustment for Illegal or Improper Activity (Over the Simplified Acquisition Threshold)
	52.203-12	 	Oct 2010	 	Limitation on Payments to Influence Certain Federal Transactions (Over $150,000)
	52.203-17	 	Apr 2014	 	Contractor Employee Whistleblower Rights and Requirements to Inform Employees of Whistleblower Rights (Over the Simplified Acquisition Threshold)
	52.204-4	 	May 2011	 	Printed or Copied Double-Sided on Postconsumer Fiber Content Paper(Over the Simplified Acquisition Threshold)
	52.204-10	 	Jul 2013	 	Reporting Executive Compensation and First-Tier Subcontract Awards ($25,000 or more)
	52.204-13	 	Jul 2013	 	System for Award Management Maintenance
	52.209-6	 	Aug 2013	 	Protecting the Government’s Interest When Subcontracting With Contractors Debarred, Suspended, or Proposed for Debarment (Over $30,000)
	52.215-2	 	Oct 2010	 	Audit and Records - Negotiation [Note:  Applies to ALL contracts funded in whole or in part with Recovery Act funds, regardless of dollar value, AND contracts over the Simplified Acquisition Threshold funded exclusively with non-Recovery Act funds.]

 

    	31

    	 

    

  

Contract Number: HHSN261201400048C

 

	FAR

CLAUSE NO.	 	DATE	 	TITLE	 
	52.215-8	 	Oct 1997	 	Order of Precedence - Uniform Contract Format	 
	52.215-10	 	Aug 2011	 	Price Reduction for Defective Certified Cost or Pricing Data (Over $700,000)	 
	52.215-12	 	Oct 2010	 	Subcontractor Cost or Pricing Data (Over $700,000)	 
	52.215-14	 	Oct 2010	 	Integrity of Unit Prices (Over the Simplified Acquisition Threshold)	 
	52.215-15	 	Oct 2010	 	Pension Adjustments and Asset Reversions (Over $700,000)
	52.215-18	 	Jul 2005	 	Reversion or Adjustment of Plans for Post-Retirement Benefits (PRB) other than Pensions
	52.215-19	 	Oct 1997	 	Notification of Ownership Changes
	52.215-21	 	Oct 2010	 	Requirements for Certified Cost or Pricing Data and Data Other Than Certified Cost or Pricing Data - Modifications
	52.215-23	 	Oct 2009	 	Limitations on Pass-Through Charges (Over the Simplified Acquisition Threshold)
	52.216-7	 	Jun 2013	 	Allowable Cost and Payment
	52.216-8	 	Jun 2011	 	Fixed Fee
	52.219-6	 	Jul 1996	 	Notice of Total Small Business Set-Aside
	52.219-8	 	May 2014	 	Utilization of Small Business Concerns (Over the Simplified Acquisition Threshold)
	52.219-14	 	Dec 1996	 	Limitations on Subcontracting
	52.222-2	 	Jul 1990	 	Payment for Overtime Premium (Over the Simplified Acquisition Threshold) (Note:  The dollar amount in paragraph (a) of this clause is $0 unless otherwise specified in the contract.)
	52.222-3	 	Jun 2003	 	Convict Labor
	52.222-21	 	Feb 1999	 	Prohibition of Segregated Facilities
	52.222-26	 	Mar 2007	 	Equal Opportunity
	52.222-35	 	Jul 2014	 	Equal Opportunity for Veterans ($100,000 or more)
	52.222-36	 	Jul 2014	 	Equal Opportunity for Workers with Disabilities
	52.222-37	 	Jul 2014	 	Employment Reports on Veterans ($100,000 or more)
	52.222-40	 	Dec 2010	 	Notification of Employee Rights Under the National Labor Relations Act (Over the Simplified Acquisition Threshold)
	52.222-50	 	Feb 2009	 	Combating Trafficking in Persons
	52.222-54	 	Aug 2013	 	Employment Eligibility Verification (Over the Simplified Acquisition Threshold)
	52.223-6	 	May 2001	 	Drug-Free Workplace
	52.223-18	 	Aug 2011	 	Encouraging Contractor Policies to Ban Text Messaging While Driving
	52.225-1	 	May 2014	 	Buy American - Supplies
	52.225-13	 	Jun 2008	 	Restrictions on Certain Foreign Purchases
	52.227-1	 	Dec 2007	 	Authorization and Consent, Alternate I (Apr 1984)
	52.227-2	 	Dec 2007	 	Notice and Assistance Regarding Patent and Copyright Infringement
	52.227-11	 	May 2014	 	Patent Rights - Ownership by the Contractor (Note:  In accordance with FAR 27.303(b)(2), paragraph (e) is modified to include the requirements in FAR 27.303(b)(2)(i) through (iv).  The frequency of reporting in (i) is annual.

 

    	32

    	 

    

 

Contract Number: HHSN261201400048C

 

	FAR

CLAUSE NO.	 	DATE	 	TITLE
	52.227-20	 	May 2014	 	Rights in Data - SBIR Program
	52.232-9	 	Apr 1984	 	Limitation on Withholding of Payments
	52.232-17	 	May 2014	 	Interest (Over the Simplified Acquisition Threshold)
	52.232-20	 	Apr 1984	 	Limitation of Cost
	52.232-23	 	May 2014	 	Assignment of Claims
	52.232-25	 	Jul 2013	 	Prompt Payment, Alternate I (Feb 2002)
	52.232-33	 	Jul 2013	 	Payment by Electronic Funds Transfer—System for Award Management
	52.232-39	 	Jun 2013	 	Unenforceability of Unauthorized Obligations
	52.233-1	 	May 2014	 	Disputes
	52.233-3	 	Aug 1996	 	Protest After Award, Alternate I (Jun 1985)
	52.233-4	 	Oct 2004	 	Applicable Law for Breach of Contract Claim
	52.242-1	 	Apr 1984	 	Notice of Intent to Disallow Costs
	52.242-3	 	May 2014	 	Penalties for Unallowable Costs (Over $700,000)
	52.242-4	 	Jan 1997	 	Certification of Final Indirect Costs
	52.242-13	 	Jul 1995	 	Bankruptcy (Over the Simplified Acquisition Threshold)
	52.243-2	 	Aug 1987	 	Changes - Cost Reimbursement, Alternate V (Apr 1984)
	52.244-2	 	Oct 2010	 	Subcontracts (Over the Simplified Acquisition Threshold), Alternate I (June 2007)
	52.244-5	 	Dec 1996	 	Competition in Subcontracting (Over the Simplified Acquisition Threshold)
	52.244-6	 	Jul 2014	 	Subcontracts for Commercial Items
	52.245-1	 	Apr 2012	 	Government Property
	52.245-9	 	Apr 2012	 	Use and Charges
	52.249-6	 	May 2004	 	Termination (Cost-Reimbursement)
	52.249-14	 	Apr 1984	 	Excusable Delays
	52.253-1	 	Jan 1991	 	Computer Generated Forms

 

b.           DEPARTMENT
OF HEALTH AND HUMAN SERVICES ACQUISITION REGULATION (HHSAR) (48 CFR CHAPTER 3) CLAUSES:

 

	HHSAR

CLAUSE NO.	 	DATE	 	TITLE
	352.202-1	 	Jan 2006	 	Definitions - with Alternate paragraph (h) (Jan 2006)
	352.203-70	 	Mar 2012	 	Anti-Lobbying
	352.216-70	 	Jan 2006	 	Additional Cost Principles
	352.222-70	 	Jan 2010	 	Contractor Cooperation in Equal Employment Opportunity Investigations
	352.227-70	 	Jan 2006	 	Publications and Publicity
	352.228-7	 	Dec 1991	 	Insurance - Liability to Third Persons
	352.233-71	 	Jan 2006	 	Litigation and Claims
	352.242-70	 	Jan 2006	 	Key Personnel

 

    	33

    	 

    

  

Contract Number: HHSN261201400048C

 

	HHSAR

CLAUSE NO.	 	DATE	 	TITLE
	352.242-73	 	Jan 2006	 	Withholding of Contract Payments
	352.242-74	 	Apr 1984	 	Final Decisions on Audit Findings

 

[End of GENERAL CLAUSES FOR A COST-REIMBURSEMENT SBIR PHASE
II CONTRACT- Rev. 08/2014].

 

ARTICLE
I.2. AUTHORIZED SUBSTITUTION OF CLAUSES

 

ARTICLE 1.1. of this SECTION is hereby modified
as follows:

 

a.           Alternate
I (October 1997) of FAR Clause 52.215-14, Integrity of Unit Prices (October 2010) is added.

 

b.           Alternate
IV (October 2010) of FAR Clause 52.215-21, Requirements for Certified Cost or Pricing Data and Data Other Than Certified
Cost or Pricing Data—Modifications (October 2010) is added.

 

ARTICLE
I.3. ADDITIONAL CONTRACT CLAUSES

 

This contract incorporates the following
clauses by reference, with the same force and effect, as if they were given in full text. Upon request, the Contracting Officer
will make their full text available.

 

a.           FEDERAL
ACQUISITION REGULATION (FAR) (48 CFR CHAPTER 1) CLAUSES

 

1.          FAR
Clause 52.215-17, Waiver of Facilities Capital Cost of Money (October 1997).

 

2.          FAR
Clause 52.219-28, Post-Award Small Business Program Representation (July 2013).

 

3.          FAR
Clause 52.225-8, Duty-Free Entry (October 2010).

 

4.          FAR
Clause 52.227-16, Additional Data Requirements (June 1987).

 

5.          FAR
Clause 52.239-1, Privacy or Security Safeguards (August 1996).

 

6.          FAR
Clause 52.242-3, Penalties for Unallowable Costs (May 2014).

 

7.          Alternate
I (April 2012), FAR Clause 52.245-1, Government Property (April 2012).

 

8.          FAR
Clause 52.246-23, Limitation of Liability (February 1997).

 

    	34

    	 

    

 

Contract Number: HHSN261201400048C

 

b.           DEPARTMENT
OF HEALTH AND HUMAN SERVICES ACQUISITION REGULATION (HHSAR) (48 CHAPTER 3) CLAUSES:

 

1.          HHSAR
Clause 352.201-70, Paperwork Reduction Act (January 2006).

 

2.          HHSAR
Clause 352.231-70, Salary Rate Limitation (August 2012).

 

Note: The Salary
Rate Limitation is at the Executive Level II Rate.

 

See the following website for
Executive Schedule rates of pay: http://www.opm.gov/oca/.

 

(For current year rates, click
on Salaries and Wages/Executive Schedule/Rates of Pay for the Executive Schedule. For prior year rates, click on Salaries and Wages/select
Another Year at the top of the page/Executive Schedule/Rates of Pay for the Executive Schedule. Rates are effective January 1 of
each calendar year unless otherwise noted.)

 

c.           NATIONAL
INSTITUTES OF HEALTH (NIH) RESEARCH CONTRACTING (RC) CLAUSES:

 

The following clauses are attached and made
a part of this contract:

 

ARTICLE
I.4. ADDITIONAL FAR CONTRACT CLAUSES INCLUDED IN FULL TEXT

 

This contract incorporates the following
clauses in full text.

 

a.           DEPARTMENT
OF HEALTH AND HUMAN SERVICES ACQUISITION REGULATION (HHSAR) (48 CHAPTER 3) CLAUSES:

 

THERE ARE NO APPLICABLE CLAUSES IN THIS
SECTION.

 

    	35

    	 

    

  

Contract Number: HHSN261201400048C

 

PART III - LIST OF DOCUMENTS, EXHIBITS AND OTHER ATTACHMENTS

 

SECTION
J - LIST OF ATTACHMENTS

 

The following documents are attached and
incorporated in this contract:

 

1.           Statement
of Work

 

Statement of Work - Phase II, dated 9/4/2014,
3 pages.

 

2.           Invoice/Financing
Request and Contract Financial Reporting Instructions for NIH Cost- Reimbursement Type Contracts, NIH(RC)-4

 

Invoice/Financing Request and Contract Financial
Reporting Instructions for NIH Cost-Reimbursement Type Contracts, NIH(RC)-4, (7/13), 6 pages.

 

3.           Disclosure
of Lobbying Activities, SF-LLL

 

Disclosure of Lobbying Activities, SF-LLL,
dated 7/97, 2 pages.

 

4.           Government
Property - Schedule

 

Government Property - Schedule I-A, dated
9/4/14, 1 page.

 

5.           Report
of Government Owned, Contractor Held Property

 

Report of Government Owned, Contractor Held
Property, dated 3/2008, 1 page. Located at: http://oamp.od.nih.gov/sites/default/files/DGS/contracting-forms/Govt-Owned-Prop.pdf

 

6.           NIH
Small Business Innovation Research (SBIR) Program Life Cycle Certification

 

NIH Small Business Innovative Research (SBIR)
Program Life Cycle Certification, 3 pages.

 

    	36

    	 

    

  

Contract Number: HHSN261201400048C

 

PART IV - REPRESENTATIONS AND INSTRUCTIONS

 

SECTION
K - REPRESENTATIONS AND CERTIFICATIONS

 

The following documents are incorporated
by reference in this contract:

 

1.          Annual
Representations and Certifications are completed and located in The System for Award Management (SAM) website (http://www.sam.gov).
This includes the changes identified in paragraph (b) of the FAR provision 52.204-8, Annual Representations and Certifications,
contained in the Contractor’s proposal.

 

2.          NIH
Representations & Certifications, dated 2/24/14

 

3.          Human
Subjects Assurance Identification Number FWA00003136.

 

END of the SCHEDULE

 

(CONTRACT)

 

    	37

    	 

    

  

Attachment 1: Statement of Work

 

HHSN261201400048C

 

Enumeral Biomedical Corp.

  

    	 

    	 

    

  

Statement of Work (Phase II) Dated 9/4/14

Contract No. HHSN261201400048C

 

	STATEMENT OF WORK (Phase II)
	 	 
	TITLE:	“Deployment of prototype system for detection of multiple analytes in small tissue samples”
	PRINCIPAL INVESTIGATOR(S): 	Arthur Tinkelenberg, PhD 
	PROJECT DURATION:	24 Months
	COMPANY:	Enumeral Biomedical Corp
	SUBCONTRACTORS:	*

 

I.           Background
Information and Objectives

 

A.           Background
Information

 

This proposal will build on the successful
efforts from Phase I, which served to characterize the technology’s accuracy and limits of detection and provide proof of
concept data on mucosal biopsy samples from patients with colorectal cancer. We aim to (1) Develop a prototype analytical system
incorporating Enumeral’s technology, including automation, software and data analysis and (2)Test prototypes on clinical
samples in collaborating academic laboratories to demonstrate clinical utility and advantages over analytical current techniques.

 

Our collaborators include *.

 

The use of Enumeral’s platform to
understand * can potentially have a significant impact on early cancer diagnosis, understanding mechanisms of disease progression,
and, ultimately development of novel, effective, and safe immunotherapies.

 

B.           Technical
Objectives

 

The technical objectives of this proposal
are to (1) Develop a prototype analytical system incorporating Enumeral’s technology, including automation, software and
data analysis (Tasks 1-5) and (2)Test prototypes on clinical samples in collaborating academic laboratories to demonstrate clinical
utility and advantages over analytical current techniques (Tasks 6-8).

 

Objective 1: Develop a prototype
analytical system incorporating Enumeral’s technology, including automation, software and data analysis

 

Task 1 (Months 1-6): Design, source,
and construct a prototype detection system. Quantitative milestones for this task comprise *

 

	Comparison	 	Quantitative Metric	 	Reasoning
	Milestone 1.1 Spot Assays	 	
        -    *

        -    *
	 	*
	
        Milestone 1.2

        Fluorescent

        Microbeads
	 	-    *	 	*
	Milestone 1.3 Cellular Secretion (PBMCs)	 	
        -    *

        -    *

        -    *
	 	*

 

    	 

    	 

    

 

Statement of Work (Phase II) Dated 9/4/14

Contract No. HHSN261201400048C

 

Task 2 (Months 1-10): Optimization
of *

 

Milestone 2.1: The proposed loading
procedure results in *

 

Milestone 2.2: The automation of
cell loading step produces *

 

Task 3 (Months 1-8): Adaptation and
optimization of integrated software platform

 

Milestone 3.1: Integrated software
package can run a protocol that *.

 

Task 4 (Months 9-10): Develop assays
to be used during system deployment

 

Milestone 4.1: Standard operating
procedures will be written encompassing assays for * (Task 6 and Task 7)

 

Task 5 (Month 11): Prepare for deployment

 

Milestone 5.1: Training is performed,
and procedural feedback is received, for end users at *

 

Objective 2: Test prototypes on clinical
samples in collaborating academic laboratories to demonstrate concordance, clinical utility and advantages over analytical current
techniques.

 

Task 6 (Months 12-17): Deploy platform
to *

 

Milestone 6.1: Scientists at * collect
and analyze data from *

 

Task 7 (Months 18-23): Deploy to
*

 

Milestone 7.1: Scientists at * collect
and analyze data from *

 

Task 8 (Month 24): Program Analysis,
Defining Steps to Commercialization

 

Milestone 8.1: A report summarizing
the data collected, concordance with previous results, any significant results of analysis, and the potential for * based on the
experiments performed.

 

Milestone 8.2: A summary of the
end-user observations, identifying the key factors that should be considered in the efforts to progress from a prototype system
to a commercial device.

 

    	 

    	 

    

 

Statement of Work (Phase II) Dated 9/4/14

Contract No. HHSN261201400048C

 

II.          Services
to be Performed

 

A.           General
Requirements

 

1.          The
contractor shall independently perform all work and furnish all labor, materials, supplies, equipment, and services (except as
otherwise specified in the contract).

 

2.          All
work will be monitored by the Government Project Officer identified in Section G of the contract.

 

    	 

    	 

    

 

Statement of Work (Phase II) Dated 9/4/14

Contract No. HHSN261201400048C

 

B.           Specific
Requirements

 

Phase II
Milestones and Timeline

 

	 	 	 	 	Year
    1	 	Year
    2
	 	 	 	 	Mo
    1-3	 	Mo
    4-6	 	Mo
    7-9	 	Mo
    10-12	 	Mo
    13-15	 	Mo
    16-18	 	Mo
    19-21	 	Mo
    22-24
	Objective
    1	 	———	 	———	 	———	 	———	 	 	 	 	 	 	 	 
	Task 1	 	Milestone 1.1 	 	X	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	Milestone 1.2 	 	X	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	Milestone 1.3	 	 	 	X	 	 	 	 	 	 	 	 	 	 	 	 
	Task 2	 	Milestone 2.1 	 	 	 	X	 	 	 	 	 	 	 	 	 	 	 	 
	 	 	Milestone 2.2	 	 	 	 	 	 	 	X	 	 	 	 	 	 	 	 
	Task 3	 	Milestone 3.1 	 	 	 	 	 	X	 	 	 	 	 	 	 	 	 	 
	Task 4	 	Milestone 4.1 	 	 	 	 	 	 	 	X	 	 	 	 	 	 	 	 
	Task 5	 	Milestone 5.1	 	 	 	 	 	 	 	X	 	 	 	 	 	 	 	 
	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Objective
    2	 	 	 	 	 	 	 	———	 	———	 	———	 	———	 	———
	Task 6 	 	Milestone 6.1 	 	 	 	 	 	 	 	 	 	 	 	X	 	 	 	 
	Task 7	 	Milestone 7.1 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	X
	Task 8	 	Milestone 8.1 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	X
	 	 	Milestone 8.2	 	 	 	 	 	 	 	 	 	 	 	 	 	 	 	X

 

    	 

    	 

    

  

Attachment 2: Invoice/Financing for Cost
Reimbursement Contracts, NIH (RC)-4

 

HHSN261201400048C

 

Enumeral Biomedical Corp.

  

    	 

    	 

    

  

INVOICE/FINANCING
REQUEST AND CONTRACT FINANCIAL REPORTING

 INSTRUCTIONS FOR NIH COST-REIMBURSEMENT CONTRACTS, NIH(RC)-4

 

Format: Submit payment requests
on the Contractor’s self-generated form in the manner and format prescribed herein and as illustrated in the Sample Invoice/Financing
Request. Standard Form 1034, Public Voucher for Purchases and Services Other Than Personal, may be used in lieu of the Contractor’s
self-generated form provided it contains all of the information shown on the Sample Invoice/Financing Request. DO NOT include
a cover letter with the payment request.

 

Number of Copies: Submit payment
requests in the quantity specified in the Invoice Submission Instructions in Section G of the Contract Schedule.

 

Frequency: Payment requests shall
not be submitted more frequently than once every two weeks in accordance with the Allowable Cost and Payment Clause incorporated
into this contract. Small business concerns may submit invoices/financing requests more frequently than every two weeks.

 

Cost Incurrence Period: Costs incurred
must be within the contract performance period or covered by precontract cost provisions.

 

Billing of Costs Incurred: If billed
costs include (1) costs of a prior billing period, but not previously billed, or (2) costs incurred during the contract period
and claimed after the contract period has expired, the Contractor shall cite the amount(s) and month(s) in which the costs were
incurred.

 

Contractor’s Fiscal Year: Prepare
payment requests in such a manner that the Government can identify costs claimed with the Contractor’s fiscal year.

 

Currency: All NIH contracts are
expressed in United States dollars. When the Government pays in a currency other than United States dollars, billings shall be
expressed, and payment by the Government shall be made, in that other currency at amounts coincident with actual costs incurred.
Currency fluctuations may not be a basis of gain or loss to the Contractor. Notwithstanding the above, the total of all invoices
paid under this contract shall not exceed the United States dollars authorized.

 

Costs Requiring Advance Approval: Costs
requiring advance approval by the Contracting Officer, which are not set forth in the Contract Schedule shall be identified by
the Contracting Officer’s Authorization (COA) Number as a separate expenditure category on the payment request. In addition,
the Contractor shall show any cost limitation or ceiling set forth in the Contract Schedule, i.e. an Advance Understanding, as
a separate expenditure category on the payment request.

 

Invoice/Financing Request Identification:
Identify each payment as either:

 

(a)          Interim
Invoice/Contract Financing Request: These are interim payment requests submitted during the contract performance period.

 

    	 

    	 

    

 

(b)          Completion
Invoice: Submit the completion invoice promptly upon completion of the work, but no later than one year from the contract
completion date, or within 120 days after settlement of the final indirect cost rates covering the year in which the contract
is physically complete (whichever date is later). The Contractor shall submit the completion invoice when all costs have been
assigned to the contract and all performance provisions have been completed.

 

(c)          Final
invoice: A final invoice may be required after the amounts owed have been settled between the Government and the Contractor
(e.g., resolution of all suspensions and audit exceptions).

 

Preparation and Itemization of the
Invoice/Financing Request:

 

The Contractor shall furnish the information
set forth in the instructions below. The instructions are keyed to the entries on the Sample Invoice/Financing Request. All
information must be legible or the invoice will be considered improper and returned to the Contractor.

 

(a)          Designated
Billing Office Name and Address: Enter the designated billing office name and address, as identified in the Invoice Submission
Instructions in Section G of the Contract Schedule.

 

(b)          Contractor’s
Name, Address, Point of Contact, TIN, and DUNS or DUNS+4 Number: Show the Contractor’s name and address exactly as they
appear in the contract. Any invoice identified as improper will be sent to this address. Also include the name, title, phone number,
and e-mail address of the Point of Contact in case of questions. If the remittance name differs from the legal business name,
both names must appear on the invoice. Provide the Contractor’s Federal Taxpayer Identification Number (TIN) and Data Universal
Numbering System (DUNS) or DUNS+4 number. The DUNS number must identify the Contractor’s name and address exactly as stated
in the contract, and as registered in the System for Award Management (SAM) database.

 

When an approved assignment of claims has
been executed, the Contractor shall provide the same information for the assignee as is required for the Contractor (i.e., name,
address, point of contact, TIN, and DUNS number), with the remittance information clearly identified as such.

 

(c)          Invoice/Financing
Request Number: Identify each payment request by a unique invoice number, which can only be used one time regardless of the
number of contracts or orders held by an organization. For example, if a contractor has already submitted invoice number 05 on
one of its contracts or orders, it cannot use that same invoice number on any other contract or order. Payment requests with duplicate
invoice numbers will be considered improper and returned to the contractor.

 

The NIH does not prescribe a particular
numbering format but suggests using a job or account number for each contract and order followed by a sequential invoice number
(example: 8675309-05). Invoice numbers are limited to 30 characters. There are no restrictions on the use of special characters,
such as colons, dashes, forward slashes, or parentheses.

 

    	 

    	 

    

  

If all or part of an invoice is suspended
and the contractor chooses to reclaim those costs on a supplemental invoice, the contractor may use the same unique invoice number
followed by an alpha character, such as “R” for revised (example: 8675309-05R).

 

(d)          Date
Invoice/Financing Request Prepared: Insert the date the payment request is prepared.

 

(e)          Contract
Number and Order Number (if applicable): Insert the contract number and order number (as applicable).

 

(f)          Contract
Title: Insert the contract title exactly as it appears on the cover page of the contract and/or Section G of the Contract
Schedule.

 

(g)          Current
Contract Period of Performance: Insert the contract start date/effective date through the current completion date of the contract.

 

(h)          Total
Estimated Cost of Contract/Order: Insert the total estimated cost of the contract, exclusive of fee. If billing under an order,
insert the total estimated cost of the order, exclusive of fee. For contracts/orders with options or incremental funding provisions,
enter the amount currently obligated and available for payment.

 

(i)          Total
Fixed-Fee: Insert the total fixed-fee (where applicable). For contracts/orders with options or incremental funding provisions,
enter the amount currently obligated and available for payment (where applicable). Note: If the contract provides for
another type of Fee, i.e. Award or Incentive Fee, insert the amount available to be earned as identified in the contract and indicate
the type of fee to be billed on the payment request.

 

(j)          Two-Way/Three-Way
Match: Identify whether payment is to be made using a two-way or three-way match. To determine required payment method, refer
to the Invoice Submission Instructions in Section G of the Contract Schedule.

 

(k)          Office
of Acquisitions: Insert the name of the Office of Acquisitions, as identified in the Invoice Submission Instructions in Section
G of the Contract Schedule.

 

(l)          Central
Point of Distribution: Insert the Central Point of Distribution, as identified in the Invoice Submission Instructions in Section
G of the Contract Schedule.

 

(m)          Billing
Period: Insert the beginning and ending dates (month, day, and year) of the period in which costs were incurred and for which
reimbursement is claimed.

 

(n)          Amount
Billed - Current Period: Insert the amount claimed for the current billing period by major cost element, including any adjustments
and fee. If the Contract Schedule contains separately priced line items, identify the contract line item(s) on the payment request
and include a separate breakdown (by major cost element) for each line item.

 

    	 

    	 

    

  

(o)          Amount
Billed - Cumulative: Insert the cumulative amounts claimed by major cost element, including any adjustments and fee. If the
Contract Schedule contains separately priced line items, identify the contract line item(s) on the payment request and include
a separate breakdown (by major cost element) for each line item.

 

(p)          Direct
Costs: Insert the major cost elements. For each element, consider the application of the paragraph entitled “Costs Requiring
Prior Approval” on page 1 of these instructions.

 

1)          Direct Labor: Include salaries
and wages paid (or accrued) for direct performance of the contract.

 

For Level of Effort contracts only, the
Contractor shall provide the following information on a separate sheet of paper attached to the payment request:

 

		-	hours or percentage of effort and cost by labor category
                                         (as specified in the Level of Effort Article in Section F of the Contract Schedule) for
                                         the current billing period, and

 

		-	hours or percentage of effort and cost by labor category
                                         from contract inception through the current billing period. (NOTE: The Contracting Officer
                                         may require the Contractor to provide additional breakdown for direct labor, such as
                                         position title, employee name, and salary or hourly rate.)

 

2)          Fringe Benefits: List any fringe
benefits applicable to direct labor and billed as a direct cost. Cite the rate(s) used to calculate fringe benefit costs, if applicable.

 

3)           Accountable
Personal Property: Include permanent research equipment and general purpose equipment having a unit acquisition cost of $1,000
or more, with a life expectancy of more than two years, and sensitive property regardless of cost (see the HHS Contractor’s
Guide for Contract of Government Property). Show permanent research equipment separate from general purpose equipment.

 

On a separate sheet of paper attached to
the payment request, list each item for which reimbursement is requested. Precede the item with an asterisk (*) if the equipment
is below the $1,000 approval level. Include reference to the following (as applicable):

 

		-	item number for the specific piece of equipment listed
                                         in the Property Schedule, and,

 

		-	Contracting Officer Authorization (COA) number, if the
                                         equipment is not covered by the Property Schedule.

 

The Contracting Officer may require the
Contractor to provide further itemization of property having specific limitations set forth in the contract.

 

    	 

    	 

    

  

4)          Materials
and Supplies: Include equipment with unit costs of less than $1,000 or an expected service life of two years or less, and
consumable material and supplies regardless of amount.

 

5)          Premium Pay: List remuneration in
excess of the basic hourly rate.

 

6)          Consultant
Fee: List fees paid to consultants. Identify consultant by name or category as set forth in the contract or COA, as well as
the effort (i.e., number of hours, days, etc.) and rate billed.

 

7)          Travel:
Include domestic and foreign travel. Foreign travel is travel outside of the United States and its territories and possessions.
However, for an organization located outside the United States and its territories and possessions, foreign travel means travel
outside that country. Foreign travel must be billed separately from domestic travel.

 

8)          Subcontract Costs: List subcontractor(s)
by name and amount billed.

 

9)          Other:
List all other direct costs in total unless exceeding $1,000 in amount. If over $1,000, list cost elements and dollar amounts
separately. If the contract contains restrictions on any cost element, that cost element must be listed separately.

 

(q)          Cost
of Money (COM): Cite the COM factor and base in effect during the time the cost was incurred and for which reimbursement is
claimed.

 

(r)           Indirect
Costs: Identify the indirect cost base (IDC), indirect cost rate, and amount billed for each indirect cost category.

 

(s)           Fixed-Fee:
Cite the formula or method of computation for fixed-fee, if applicable. The fixed-fee must be claimed as provided for by the
contract. Note: If the contract provides for another type of Fee, i.e. Award or Incentive Fee, provide the same
documentation for the amount claimed.

 

(t)            Total
Amounts Claimed: Insert the total amounts claimed for the current and cumulative periods.

 

(u)           Adjustments:
Include amounts conceded by the Contractor, outstanding suspensions, and/or disapprovals subject to appeal.

 

(v)           Grand
Totals

 

(w)          Certification:
The Contractor shall include the following certification at the bottom of each payment request:

 

“Pursuant to authority vested in
me, I certify that this voucher is correct and proper for payment.”

 

    	 

    	 

    

  

Note: The contract may require
additional certifications (See Invoice Submission Instructions in Section G of the Contract Schedule)

 

The Contracting Officer may require the Contractor to
submit detailed support for costs claimed on one or more interim payment requests.

 

FINANCIAL REPORTING INSTRUCTIONS:

 

These instructions correspond to the Columns
on the Sample Invoice/Financing Request.

 

Column A - Expenditure Category: Enter
the expenditure categories required by the contract.

 

Column B - Cumulative Percentage of
Effort/Hrs. - Negotiated: Enter the percentage of effort or number of hours agreed to for each employee or labor category
listed in Column A.

 

Column C - Cumulative Percentage of
Effort/Hrs. - Actual: Enter the percentage of effort or number of hours worked by each employee or labor category listed in
Column A.

 

Column D - Amount Billed - Current:
Enter amounts billed during the current period.

 

Column E - Amount Billed - Cumulative:
Enter the cumulative amounts to date.

 

Column F - Cost at Completion: Enter
data only when the Contractor estimates that a particular expenditure category will vary from the amount negotiated. Realistic
estimates are essential.

 

Column G - Contract Amount: Enter
the costs agreed to for all expenditure categories listed in Column A.

 

Column H - Variance (Over or Under):
Show the difference between the estimated costs at completion (Column F) and negotiated costs (Column G) when entries have
been made in Column F. This column need not be filled in when Column F is blank. When a line item varies by plus or minus 10 percent,
i.e., the percentage arrived at by dividing Column F by Column G, an explanation of the variance should be submitted. In the case
of an overrun (net negative variance), this submission shall not be deemed as notice under the Limitation of Cost Clause
in the contract.

 

Modifications: List all new modification(s)
(not previously reported) in the amount negotiated for an item in the appropriate cost category.

 

Expenditures Not Negotiated: An
expenditure for an item for which no amount was negotiated (e.g., at the discretion of the Contractor in performance of its contract)
should be listed in the appropriate cost category and all columns filled in, except for G. Column H will of course show a 100
percent variance and will be explained along with those identified under H above.

 

    	 

    	 

    

  

	SAMPLE INVOICE/FINANCING REQUEST AND CONTRACT
    FINANCIAL REPORT
	 
	(a)   Designated
                           Billing Office Name and Address:

                           National Institutes of Health

                           Office of Financial Management

                           Commercial Accounts

                           2115 East Jefferson Street, Room 4B432,

                           MSC 8500

                           Bethesda, MD 20892-8500

         

        (b)   Contractor’s
        Name, Address, Point of Contact,

        TIN, and DUNS or DUNS+4 Number:

        ABC CORPORATION

        100 Main Street

        Anywhere, U.S.A. Zip+4

        Name, Title, Phone Number, and E-mail

        Address of Contractor’s Point of Contact.

        DUNS or DUNS+4: _________________

        TIN: ______________________________
	(c)   Invoice/Financing
                           Request No.: ___________

        (d)   Date
        Invoice/Financing Request Prepared:

        ______________________________________

        (e)   Contract
No. and Order No. (if applicable):

_______________________________________

        (f)    Contract
        Title:

        _______________________________________

        (g)   Current
Contract Period of Performance:

_______________________________________

        (h)   Total
Estimated Cost of Contract/Order:

_______________________________________

        (i)    Total
        Fixed Fee (if applicable): ____________

         

        (j)    Two-Way
        Match: _____

        Three-Way Match: _____

        (k)   Office
of Acquisitions: __________________

        (1)   Central
Point of Distribution: ______________

	 	 
	(m)          This invoice/financing
    request represents reimbursable costs for the period from _____ to _____.

 

	 	 	Cumulative %

     of Effort/Hrs	 	Amount Billed	 	 	 	 	 	 
	Expenditure Category*
    

    A	 	Neg.

        B
	 	Actual

        C
	 	(n)

        Current

        D
	 	(o)

        Cum

        E
	 	Cost at

Comp 

    F	 	Contract

        Value

        G
	 	Variance

        H

	(p)          Direct Costs:	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	(1)   Direct
    Labor	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	(2)   Fringe
    Benefits ___%	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	(3)   Accountable
    Property	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	(4)   Materials
    & Supplies	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	(5)   Premium
    Pay	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	(6)   Consultant
    Fees	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	(7)   Travel	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	(8)   Subcontracts	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	(9)   Other	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	Total Direct Costs	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	(q)    Cost of Money ___%	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	(r)     Indirect Costs ___%	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	(s)    Fixed Fee ___%	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	(t)     Total Amount Claimed	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	(u)    Adjustments	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	(v)    Grand Totals	 	 	 	 	 	 	 	 	 	 	 	 	 	 

 

“Pursuant to authority vested in me, I certify
that this voucher is correct and proper for payment.”

 

	 	 	 
	(Name of Official) 	 	(Title)

 

* Attach details as specified in the contract or requested
by the Contracting Officer

 

    	 

    	 

    

  

Attachment 3: Disclosure of Lobbying
Activities

 

HHSN261201400048C

 

Enumeral Biomedical Corp.

 

 

    	 

    	 

    

  

	Approved
                                         by omb

        0348-0046

        DISCLOSURE OF LOBBYING ACTIVITIES

        Complete this form to disclose
        lobbying activities pursuant to 31 U.S.C. 1352 

        (See reverse for public burden disclosure.)

	1.
                                         Type of Federal Action:

         ̈  a.
        contract 

              b.
        grant

              c.
        cooperative agreement

              d.
        loan

              e.
        loan guarantee

              f.
         loan insurance
	2.
                                         Status of Federal Action:

         ̈    a.
        bid/offer/application

                b.
        initial award

        c. post-award
	3.
                                         Report Type:

         ̈    a. initial filing

                b. material change 

        For Material Change Only: 

        year ______ quarter _________

        date of last report ___________

	4.
                                         Name and Address of Reporting Entity:

         ̈ Prime
         ̈ Subawardee

        Tier ________, if known:

         

         

         

        Congressional District, if known: 4c
	5.
                                         If Reporting Entity in No. 4 is a Subawardee, Enter Name and Address of Prime:

         

         

         

         

         

        Congressional District, if known:

	6.
    Federal Department/Agency:	7.
                                         Federal Program Name/Description:

         

         

         

        CFDA Number, if applicable: _______________

         

	8.
    Federal Action Number, if known:	9.
                                         Award Amount, if known:

         

        $

	10.
                                         a. Name and Address of Lobbying Registrant

        (if individual, last name, first name, MI):
	b.
                                         Individuals Performing Services (including address if different from No. 10a)

        (last name, first name, MI):

         

         

	11.
Information requested through this form is authorized by title 31 U.S.C. section 1352. This disclosure of lobbying activities
is a material representation of fact upon which reliance was placed by the tier above when this transaction was made or entered
into. This disclosure is required pursuant to 31 U.S.C. 1352. This information will be available for public inspection. Any person
who fails to file the required disclosure shall be subject to a civil penalty of not less than $10,000 and not more than $100,000
for each such failure.

                                                                                                                                    
	Signature: ________________________

                                                                                                                                                                   

        Print Name: ________________________

         

        Title: ________________________

         

        Telephone No.: ______________ Date: ______________

         

	Federal
    Use Only:	Authorized
    for Local Reproduction Standard Form LLL (Rev. 7-97)
	 	 	 	 	 

    	 

    	 

    

  

INSTRUCTIONS FOR COMPLETION OF SF-LLL,
DISCLOSURE OF LOBBYING ACTIVITIES

 

This disclosure form shall be completed
by the reporting entity, whether subawardee or prime Federal recipient, at the initiation or receipt of a covered Federal action,
or a material change to a previous filing, pursuant to title 31 U.S.C. section 1352. The filing of a form is required for each
payment or agreement to make payment to any lobbying entity for influencing or attempting to influence an officer or employee
of any agency, a Member of Congress, an officer or employee of Congress, or an employee of a Member of Congress in connection
with a covered Federal action. Complete all items that apply for both the initial filing and material change report. Refer to
the implementing guidance published by the Office of Management and Budget for additional information.

 

1.          Identify
the type of covered Federal action for which lobbying activity is and/or has been secured to influence the outcome of a covered
Federal action.

 

2.          Identify
the status of the covered Federal action.

 

3.          Identify
the appropriate classification of this report. If this is a followup report caused by a material change to the information previously
reported, enter the year and quarter in which the change occurred. Enter the date of the last previously submitted report by this
reporting entity for this covered Federal action.

 

4.          Enter
the full name, address, city, State and zip code of the reporting entity. Include Congressional District, if known. Check the
appropriate classification of the reporting entity that designates if it is, or expects to be, a prime or subaward recipient.
Identify the tier of the subawardee, e.g., the first subawardee of the prime is the 1st tier. Subawards include but are not limited
to subcontracts, subgrants and contract awards under grants.

 

5.          If
the organization filing the report in item 4 checks “Subawardee,” then enter the full name, address, city, State and
zip code of the prime Federal recipient. Include Congressional District, if known.

 

6.          Enter
the name of the Federal agency making the award or loan commitment. Include at least one organizational level below agency name,
if known. For example, Department of Transportation, United States Coast Guard.

 

7.          Enter
the Federal program name or description for the covered Federal action (item 1). If known, enter the full Catalog of Federal Domestic
Assistance (CFDA) number for grants, cooperative agreements, loans, and loan commitments.

 

8.          Enter
the most appropriate Federal identifying number available for the Federal action identified in item 1 (e.g., Request for Proposal
(RFP) number; Invitation for Bid (IFB) number; grant announcement number; the contract, grant, or loan award number; the application/proposal
control number assigned by the Federal agency). Include prefixes, e.g., “RFP-DE-90-001.”

 

    	 

    	 

    

  

9.          For
a covered Federal action where there has been an award or loan commitment by the Federal agency, enter the Federal amount of the
award/loan commitment for the prime entity identified in item 4 or 5.

 

10.        (a)
Enter the full name, address, city, State and zip code of the lobbying registrant under the Lobbying Disclosure Act of 1995 engaged
by the reporting entity identified in item 4 to influence the covered Federal action.

 

(b) Enter the full names of the individual(s)
performing services, and include full address if different from 10 (a). Enter Last Name, First Name, and Middle Initial (MI).

 

11.         The
certifying official shall sign and date the form, print his/her name, title, and telephone number.

 

According to the Paperwork Reduction Act, as amended, no persons
are required to respond to a collection of information unless it displays a valid OMB Control Number. The valid OMB control number
for this information collection is OMB No. 0348-0046. Public reporting burden for this collection of information is estimated
to average 10 minutes per response, including time for reviewing instructions, searching existing data sources, gathering and
maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding the burden estimate
or any other aspect of this collection of information, including suggestions for reducing this burden, to the Office of Management
and Budget, Paperwork Reduction Project (0348-0046), Washington, DC 20503.

 

    	 

    	 

    

  

Attachment 4: Government Property Schedule
I-A

 

HHSN261201400048C

 

Enumeral Biomedical Corp.

 

    	 

    	 

    

  

Government Property-Schedule I-A

Enumeral Biomedical Corp.

HHSN261201400048C

9/4/14

 

	 	 	Period I	 	Period

    II	 	 
	ITEM	 	Unit 

    Price	 	Unit

        Quantity
	 	Subtotal	 	Unit 

    Price	 	Unit

Quantity	 	Subtotal	 	TOTAL
	1  *	 	*	 	*	 	*	 	*	 	*	 	*	 	*
	2  *	 	*	 	*	 	*	 	*	 	*	 	*	 	*
	3  *	 	*	 	*	 	*	 	*	 	*	 	*	 	*
	TOTAL =	 	 	 	 	 	*	 	 	 	 	 	*	 	*

 

Items (2) and (3) shall be leased;
whereas, item (1) shall be purchased. Title to Government Property shall vest with the Government.

 

    	 

    	 

    

  

Attachment 5: Report of Government Owned,
Contractor Help Property

 

HHSN261201400048C

 

Enumeral Biomedical Corp.

 

    	 

    	 

    

  

	REPORT OF GOVERNMENT
    OWNED, CONTRACTOR HELD 

    PROPERTY
	CONTRACTOR:

          
	CONTRACT NUMBER
	ADDRESS	REPORT
        DATE:

         

	

 

	 	FISCAL YEAR:
	 	 
	 	 

	CLASSIFICATION	 	BEGINNING
    

    OF PERIOD	 	ADJUSTMENTS	 	END
    OF PERIOD
	 	 	#ITEMS	 	VALUE	 	GFP
    ADDED	 	CAP
    ADDED	 	DELETIONS	 	#ITEMS	 	VALUE
	LAND>=$25K	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	LAND<$25K	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	OTHER REAL>=$25K	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	OTHER REAL <$25K	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	PROPERTY UNDER CONST>=$25K	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	PROPERTY UNDER CONST<$25K	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	PLANT EQUIP>=$25K	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	PLANT EQUIP<$25K	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	SPECIAL TOOLING>=$25K	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	SPECIAL TOOLING<$25K	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	SPECIAL TEST EQUIP >=$25K	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	SPECIAL TEST EQUIP<$25K	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	AGENCY PECULIAR>=$25K	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	AGENCY PECULIAR<$25K	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	MATERIAL>=$25K (CUMULATIVE)	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	PROPERTY UNDER MFR>=$25K	 	 	 	 	 	 	 	 	 	 	 	 	 	 
	PROPERTY UNDER MFR<$25K	 	 	 	 	 	 	 	 	 	 	 	 	 	 

  

	SIGNED BY:	 	DATE SIGNED:

 

	(SIGNATURE)	 	 	 

 

	(NAME PRINTED) 	 	 	(TELEPHONE)	 

 

	(TITLE)	 	 	 

 

Report of Government Owned, Contractor Held Property (Rev 3/2008)

 

    	 

    	 

    

  

Attachment 6: NIH SBIR Program Life Cycle
Certification

 

HHSN261201200048C

 

Enumeral Biomedical Corp.

 

    	 

    	 

    

  

NIH Small Business Innovation Research
Program

Life Cycle Certification

 

All SBIR Phase I and Phase II Contractors must complete this
certification at all times set forth in the funding agreement (see § 8(h) of the SBIR Policy Directive). This includes checking
all of the boxes and having an authorized officer of the Contractor sign and date the certification each time it is required.

 

A certification is required at the following times:

 

		·	For SBIR
                                         Phase I Contractors: At the time of receiving final payment or disbursement.

 

		·	For SBIR
                                         Phase II Contractors: prior to receiving more than 50% of the total contract amount and
                                         prior to final payment or disbursement.

 

If the Contractor cannot complete this certification or cannot
ensure compliance with the certification process, it should notify the Contracting Officer immediately. If resolution cannot be
reached, the Contracting Officer will void or terminate the award, as appropriate.

 

Contract Number:

 

Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)):

 

Please read carefully the following certification statements.
The Federal government relies on the information to ensure compliance with specific program requirements during the life of the
funding agreement. The definitions for the terms used in this certification are set forth in the Small Business Act, the SBIR
Policy Directive, and also any statutory and regulatory provisions referenced in those authorities.

 

If the Contracting Officer believes that the business is not
meeting certain funding agreement requirements, the agency may request further clarification and supporting documentation in order
to assist in the verification of any of the information provided.

 

Even if correct information has been included in other materials
submitted to the Federal government, any action taken with respect to this certification does not affect the Government’s
right to pursue criminal, civil or administrative remedies for incorrect or incomplete information given in the certification.
Each person signing this certification may be prosecuted if they have provided false information.

 

The undersigned has reviewed, verified and certifies that (all
boxes must be checked):

 

1.           The
principal investigator spent more than one half of his/her time as an employee of the Contractor or has requested and received
a written deviation from this requirement from the Contracting Officer.

 

	 ̈Yes	 ̈No	Deviation approved in writing by Contracting Officer:  ____%

 

    	 

    	 

    

  

2.           All,
essentially equivalent work, or a portion of the work performed under this project (check the applicable line):

 

		 ̈	Has not been submitted for funding by another Federal agency.

 

		 ̈	Has been
                                         submitted for funding by another Federal agency but has not been funded under any other
                                         Federal grant, contract, subcontract, or other transaction.

 

		 ̈	A portion
                                         has been funded by another grant, contract, or subcontract as described in detail in
                                         the proposal and approved in writing by the Contracting Officer.

 

3.           Upon
completion of the contract it will have performed the applicable percentage of work, unless a deviation from this requirement
is approved in writing by the Contracting Officer (check the applicable line and fill in if needed):

 

		 ̈	SBIR Phase I: at least two-thirds (66 2/3%) of the research

 

		 ̈	SBIR Phase II: at least half (50%) of the research

 

		 ̈	Deviation approved in writing by the Contracting Officer:
     %

 

4.           The
work is completed and it has performed the applicable percentage of work, unless a deviation from this requirement is approved
in writing by the Contracting Officer (check the applicable line and fill in if needed).

 

		 ̈	SBIR Phase
                                         I: at least two-thirds (66 2/3%) of the research

 

		 ̈	SBIR Phase
                                         II: at least half (50%) of the research

 

		 ̈	Deviation
                                         approved in writing by the Contracting Officer:     %

 

		 ̈	N/A because
                                         work is not completed

 

5.           The
research/research and development is performed in the United States unless a deviation is approved in writing by the Contracting
Officer.

 

	 ̈Yes	 ̈No	Waiver has been granted

 

6.           The
research/research and development is performed at my facilities with my employees, except as otherwise indicated in the SBIR proposal
and approved in the contract.

 

	 ̈Yes	 ̈No	 

 

		 ̈	I will notify
                                         the Federal agency immediately if all or a portion of the work proposed is subsequently
                                         funded by another Federal agency.

 

		 ̈	I understand
                                         that the information submitted may be given to Federal, State and local agencies for
                                         determining violations of law and other purposes.

 

    	 

    	 

    

  

		 ̈	I am an
                                         officer of the business concern authorized to represent it and sign this certification
                                         on its behalf. By signing this certification, I am representing on my own behalf, and
                                         on behalf of the business concern that the information provided in this certification,
                                         the proposal, and all other information submitted in connection with the award, is true
                                         and correct as of the date of submission. I acknowledge that any intentional or negligent
                                         misrepresentation of the information contained in this certification may result in criminal,
                                         civil or administrative sanctions, including but not limited to: (1) fines, restitution
                                         and/or imprisonment under 18 U.S.C. § 1001; (2) treble damages and civil penalties
                                         under the False Claims Act (31 U.S.C. § 3729 et seq.); (3) double damages and civil
                                         penalties under the Program Fraud Civil Remedies Act (31 U.S.C. §3801 et seq.);
                                         (4) civil recovery of award funds; (5) suspension and/or debarment from all Federal procurement
                                         and nonprocurement transactions (FAR Subpart 9.4 or 2 C.F.R. part 180); and (6) other
                                         administrative penalties including termination of SBIR/STTR awards.

 

	Date
	 
	Signature
	 
	Printed Name (First, Middle, Last)
	 
	Title
	 
	Business NameExhibit 10.3

 

ENUMERAL BIOMEDICAL HOLDINGS, INC.

 

Scientific Advisory Board Agreement 

 

(Barry Buckland)

 

THIS SCIENTIFIC ADVISORY
BOARD AGREEMENT (this “Agreement”) is made and entered into as of September 14, 2014 (the “Effective
Date”), by and between Enumeral Biomedical Holdings, Inc., a Delaware corporation (the “Company”)
and Barry Buckland, Ph.D. (“Advisor”).

 

WHEREAS, the Company
and Advisor desire to enter into this Agreement pursuant to which the Company will appoint Advisor to the Company’s Scientific
Advisory Board (the “SAB”);

 

NOW, THEREFORE, for
the premises and conditions set forth herein and for consideration the receipt and sufficiency of which are hereby acknowledged,
the Company and Advisor hereby agree as follows:

 

1.          Engagement.

 

a.           The
Company is in the business of developing, researching, manufacturing and selling antibody based products and services for immunotherapies
utilizing a proprietary microarray platform (the “Business”). The Advisor has extensive experience in the Business,
and the Company seeks to benefit from the Advisor’s expertise by retaining the Advisor. The Company hereby retains the Advisor
as Chairman of the SAB, and the Advisor hereby agrees to serve as Chairman of the SAB (such services on the SAB being herein referred
to as the “Services”). The Services shall include without limitation:

 

		i.	Attend and Chair meetings of the Company’s SAB;

		 	 

		ii.	Meet with Company employees, consultants and other members
of the SAB for the purpose of reviewing goals of the Company and assisting in developing strategies for achieving such goals;

		 	 

		iii.	Selecting and prioritizing projects and key scientific
issues;

		 	 

		iv.	Providing advice and counsel on the development and enhancement
of the Company’s products;

		 	 

		v.	Provide consultation to the Company at its request, including
a reasonable amount of informal consultation over the telephone or otherwise as requested by the Company;

		 	 

		vi.	Review specific publications from time to time as may
be requested by the Company;

 

    	 

    	 

    

  

		vii.	Monitor the market place, peer community, and published
literature for potentially competitive technologies and new technologies that might enhance the Company’s business plan;

		 	 

		viii.	Recommend research and clinical studies to advance applications
of the Company’s technology, as may be agreed by the Company and Advisor from time to time; and

		 	 

		ix.	Assist in recruiting consultants and key science and
technology managers to assist the Company.

 

b.           Advisor
agrees to devote his reasonable diligent efforts to performing the Services.

 

2.          SAB
Meetings. Advisor agrees to be available for SAB meetings four (4) times per calendar year at the Company’s office
or at such other location as may be reasonably designated by the Company. Notwithstanding anything to the contrary herein, members
of the SAB may consult and meet, on a more frequent basis, as needed. If Advisor reasonably believes that he has a conflict of
interest with the subject matter to be discussed at any particular SAB meeting, Advisor, without violating any confidentiality
obligation to a third party, shall inform the Company of same, and excuse himself from such discussion.

 

3.          Compensation.
The consideration described below in this Paragraph 3 constitutes the full consideration for the Services to be provided by
Advisor to the Company under this Agreement.

 

Fees. Subject to meeting
obligations hereunder and pursuant to the payment schedule set forth in Paragraph 3.b below, the Company shall pay Advisor

 

a.           At
the rate of $300 per hour or a per diem payment of Two Thousand ($2,000) for each day that Advisor provides Services, as
appropriate for the nature of the services rendered; provided that in no event shall such per diem payments for any
continuous 12-month period exceed One Hundred Thousand Dollars ($100,000) in the aggregate, which may be increased by mutual agreement
of the parties (the “Maximum Annual Compensation”). On the Effective Date (and on each anniversary thereafter
during the Term (as defined below)) (each an “Election Date”), Advisor shall irrevocably direct the Company
to pay to Advisor all such payments up to the Maximum Annual Compensation owing for Services to be provided in the forthcoming
12-month period as either: (i) cash, or (ii) common stock of the Company, subject to vesting as set forth below. If the Advisor
elects to receive common stock, subject to vesting, the number of shares issued to the Advisor (the “Common Stock Award”)
shall be equal to an amount to be elected by the Advisor based on his or her estimate of the fees that he or she will charge the
Company for that annual period not to exceed the Maximum Annual Compensation divided by a number equal to the Company’s common
stock’s average trading price for the period from the Election Date through ten (10) trading days thereafter. Such shares
shall vest pursuant to Paragraph 3.c. If Advisor does not make such an election by the Election Date for any annual period, then
it will be assumed that the Advisor will be paid in cash for such annual period.

 

    	2

    	 

    

  

b.           Invoices.
Advisor shall submit invoices to Company on the first day of each month for all per diem payments due for Services provided
for the preceding month, specifying to Company’s reasonable satisfaction the Services performed, and the number of days for
which Advisor provided Services. Company shall pay Advisor, as either cash or through the vesting of shares of common stock, as
elected by the Advisor under Paragraph 3.a above, all Undisputed Amounts (as defined below) specified in each invoice within fifteen
(15) calendar days following receipt of such invoice. Amounts on invoices submitted by Advisor to Company are deemed accepted and
approved (“Undisputed Amounts”) unless such amount is disputed by Company in good faith in writing with a statement
of the reasons for the dispute within ten (10) calendar days of Company’s receipt of the invoice.

 

c.           Vesting
of Common Stock; Section 83(b) Election. In the event that Advisor elects to receive common stock under Paragraph 3.a,
then the Common Stock Award shall vest in monthly installments equal to the Undisputed Amount of the applicable invoice for such
month, so long as Advisor is serving on the SAB pursuant to this Agreement and is not in breach of this Agreement. Any unvested
amounts for any annual period, shall be forfeited and cancelled at the end of such annual period. Advisor has consulted a tax advisor
and is aware of the consequences of making a timely election under Section 83(b) of the Internal Revenue Code (the “83(b)
Election”) and the consequences of not making such an election. Advisor is aware such election must be made with the Internal
Revenue Service (“IRS”) within 30 days of the issuance of shares of common stock (the IRS makes no exceptions) and
that Advisor is solely responsible for making the 83(b) Election. If an 83(b) Election is made, Advisor must meet other requirements
including filing a copy of the original 83(b) Election with Advisor’s tax return and providing a copy to the Company.

 

d.           Expenses.
The Company shall reimburse Advisor for any actual expenses incurred by Advisor while rendering the Services so long as such
expenses are reasonable and necessary, appropriately documented and approved by the Company in advance. Company may request
additional information with respect to the expenses and the Advisor shall provide such material to the Company.

 

4.          Term;
Termination; Survival. 

 

a.           Unless
terminated earlier under Paragraph 4.b below, this Agreement will terminate on the second (2nd) anniversary of the Effective
Date (the “Term”). Following the expiration of the Term, the parties may renew this Agreement on a year by year
basis upon mutual agreement.

 

b.           Prior
to the expiration of the Term, this Agreement may be terminated with or without cause by either party upon 30 days prior written
notice. Such termination shall not relieve Advisor or the Company of any obligations hereunder which by their terms are intended
to survive the termination of Advisor’s engagement with the Company, including but not limited to the obligations of Paragraphs
5, 7, 8, 9, and 10, which survive the termination of this Agreement.

 

5.          Restrictions
on Competitive Activities. So long as this Agreement continues in effect and for a period of one (1) year following termination
of this Agreement, Advisor shall not, subject to Paragraph 1.c above, without the written approval of the Company, alone or as
a partner, officer, member, director, consultant, employee, stockholder or otherwise:

 

    	3

    	 

    

  

a.           Engage
in any employment, consulting or business activity, occupation or other activity that is a Competitive Business; provided, however,
that the holding by the Advisor of any investment in any security shall not be deemed to be a violation of this Paragraph 5 if
such investment does not constitute over five percent (5%) of the outstanding issue of such security;

 

b.           Induce
or attempt to induce any licensor, licensee, corporate partner, customer, dealer, supplier or distributor of the Company to reduce
or restrict such person’s business with the Company; or

 

c.           Solicit
any of Company’s consultants or employees to leave the employ of Company or hire or cause to be hired any person who was
during or for six (6) months after the termination of the Advisor’s engagement by the Company, a consultant or employee of
the Company.

 

The above restrictions in Paragraph 5.a
shall not be deemed to prohibit Advisor from taking a position as a faculty member or researcher with any university, college,
hospital or other research, or teaching based nonprofit institution (each, a “Principal Institution”); provided,
however, that Advisor shall not in such capacity perform any services for, or which is intended to be for, any Competitive Business
(including, without limitation, under or through any sponsored research or other research, development or consulting arrangement
with such Principal Institution, even if Advisor is not the originator of such arrangement). The parties agree that this covenant
is supported by independent consideration.

 

For purposes of this Paragraph 5, “Competitive
Business” shall mean any for-profit business (other than the Company, but, solely for purposes of clarification, including,
without limitation, a for-profit business of a non-profit entity) that involves discovery or development, or marketing of discovery
platforms, therapeutics or other clinical services, products, diagnostics, and the like, for the diagnosis, monitoring, or treatment
of any disease or condition which is a Competing Product or Service in the Business. A “Competing Product or Service”
shall mean any product, process, or service of any person or organization other than the Company or any of its subsidiaries, in
existence or under development, (i) which is identical to, substantially the same as, in direct competition with, or an adequate
substitute for any product, process, or service of the Company or any of its subsidiaries, in existence or under actual development
by the Company as indicated in good faith by the Company in writing to the Advisor or is in existence or under actual development
within two (2) years after written disclosure to the Advisor, and (ii) which is marketed or distributed to compete with such product,
process or service marketed or distributed by or on behalf of the Company or any of its subsidiaries.

 

6.          Independent
Contractors. The Company and Advisor are independent contractors and neither this Agreement nor the Services to be rendered
hereunder shall for any purpose whatsoever or in any way or manner create any employer-employee or partnership relationship between
the parties. Advisor shall not be entitled to any benefits, coverage or privileges generally provided to employees of the Company
and the Company shall not be required to maintain workers’ compensation coverage for the Advisor.

 

    	4

    	 

    

 

7.          No
Improper Disclosure or Use of Materials. The Advisor shall not improperly use or disclose to or for the Company’s
benefit any confidential information or trade secrets of (i) any former, current or future employer, (ii) any person or other legal
entity to whom the Advisor has previously provided, currently provides or may within the term of this Agreement provide consulting
services, or (iii) any other person to whom the Advisor owes an obligation of confidentiality. The Advisor shall not bring onto
the premises of the Company any unpublished documents or any property belonging to any person or other legal entity referred to
in any of Section 7(i), (ii) or (iii) unless consented to in writing by the party which owns such information and has a right to
consent to its disclosure. Without limiting the generality of the foregoing, the Advisor shall not disclose to the Company, and
shall not use for the Company’s benefit, any information relating to or arising out of Advisor’s work conducted at
his present employer, or utilizing the funds, personnel, facilities, materials or other resources of his present employer, until
such information has been published

 

8.          Confidentiality.

 

a.           Advisor
may disclose to the Company any information that Advisor would normally freely disclose to other members of the scientific community
at large, whether by publication, by presentation at seminars, or in informal scientific discussions. However, Advisor shall not
disclose to the Company information that (i) is proprietary to the Employer and (ii) is not generally available to the public,
except through formal technology transfer procedures.

 

b.           During
the course of his engagement with Company, Advisor may have access to, learn of, or participate in the development of Company Confidential
Information. Advisor agrees that he will not at any time publish or disclose to others or use for his own benefit or the benefit
of others any research, development, engineering and manufacturing data, plans, designs, formulae, processes, specifications, techniques,
trade secrets, financial information, customer or supplier lists or other information that becomes known to or developed or discovered
by him as a result of his relationship with the Company, including any such information which is, or pursuant to the terms hereof
becomes, the property of the Company or any of its clients, customers, consultants, licensors, licensees, or affiliates during
the period of his engagement with the Company (“Company Confidential Information”). Upon termination of this
Agreement or sooner if requested by the Company, the Advisor shall return to the Company any and all Company Confidential Information.
Advisor understands and agrees that his confidentiality obligations under this Paragraph 8 shall continue both during his engagement
and after termination of his engagement until such Company Confidential Information becomes generally available to the public through
legitimate means. Specific information which Advisor may receive, observe, perceive, create, develop, or learn while engaged by
the Company shall not be deemed to be generally available to the public merely because such specific information is embraced by
more general information which is generally available to the public.

 

c.           For
the avoidance of doubt, Company Confidential Information shall not include information generated by Advisor (whether alone or with
others) unless Advisor generated such information (i) during the course of performing the Services, and (ii) outside the
scope of Advisor’s employment with Employer.

 

    	5

    	 

    

  

9.          Disclosure
of Current and Future Potential Conflicts. The Advisor represents that he is free to enter into this Agreement and that
his performance of all of the terms of this Agreement and of all of his duties as a consultant to the Company do not and will not
breach (i) any agreement to keep in confidence information acquired by the Advisor in confidence or in trust, (ii) any agreement
to assign to any third party inventions made by the Advisor, or (iii) any agreement not to compete against the business of any
third party. Advisor further represents and covenants that he has not made and will not make any agreements in conflict with this
Agreement.

 

10.         Disclosure
and Assignment of Inventions.

 

a.           SAB
Inventions Defined. As used herein, “SAB Inventions” shall mean materials, inventions, discoveries,
ideas, developments, methods and processes (whether or not patentable or copyrightable or constituting trade secrets) conceived,
made or discovered by Advisor (whether alone or with others or whether or not reduced to practice) as a result of Advisor’s
performance of the Services, Advisor’s engagement as chairman of the SAB under this Agreement, or as a result of or derived
from Company Confidential Information.

 

b.           Disclosure
of SAB Inventions. Advisor shall promptly and fully disclose in writing to the Company all SAB Inventions.

 

c.           Assignment
of SAB Inventions. Advisor hereby assigns to the Company (or as otherwise directed by the Company) his full right, title
and interest to, all SAB Inventions. Advisor agrees to execute any and all applications for domestic and foreign patents, copyrights
or other proprietary rights and to do such other acts (including, among others, the execution and delivery of instruments of further
assurance or confirmation) requested by the Company to assign the SAB Inventions to the Company and to permit the Company to file,
obtain and enforce any patents, copyrights or other proprietary rights in the SAB Inventions. Advisor understands and agrees that
the Company shall determine, in its sole and absolute discretion, whether an application for patent, for copyright, for mask work
registration, or for any other intellectual property right shall be filed on any SAB Invention, and whether such an application
shall be prosecuted or abandoned prior to issuance or registration. Advisor acknowledges that all works of authorship and all mask
works that fall within the scope of his engagement under this Agreement are owned by the Company and are works made for hire. Advisor
waives all “moral rights” in connection with any SAB Invention. Notwithstanding anything to the contrary herein, the
Company shall have no rights by reason of this Agreement in any publication, invention, discovery, improvement, or other intellectual
property whatsoever, whether or not publishable, patentable, or copyrightable, which is developed within the scope of Advisor’s
employment with Employer. The Company acknowledges and agrees that it will enjoy no priority or advantage as a result of the engagement
created by this Agreement in gaining access, whether by license or otherwise, to any proprietary information or intellectual property
that arises from any research undertaken by Advisor in his employment with Employer.

 

11.         Notes
and Memoranda. Advisor agrees that he will not make any notes or memoranda relating to the Services or the Business otherwise
than for the benefit of the Company and will not at any time use or permit to be used any such notes or memoranda otherwise than
for the benefit of the Company. All such notes and memoranda are the exclusive property of the Company.

 

    	6

    	 

    

  

12.         Publications.
If any manuscript that Advisor, either by himself or with others, seeks to publish contains information relating to the Services
or the Business, Advisor agrees to submit to the Company an early draft of such manuscript in sufficient time to enable the Company
to ascertain whether the manuscript contains Company Confidential Information or discloses a SAB Invention to which the Company
has rights. Advisor shall cooperate with the Company in this respect and shall delete from the manuscript any Company Confidential
Information as requested by the Company and shall assist the Company as requested by the Company in filing for patent protection
(prior to publication of such manuscript) for any SAB Inventions in and to which the Company has rights. Notwithstanding the foregoing,
the obligations of Advisor under this Paragraph 12 shall not apply to the publication of information: (i) relating to inventions,
discoveries, developments, methods and processes that Advisor is not required to assign to the Company under Paragraph 10 hereof,
or (ii) not deemed Company Confidential Information.

 

13.         No
Conflicts. Advisor is not subject to any agreement, restriction, obligation, right or interest in anyone (including without
limitation, the Employer) limiting in any way the scope of this Agreement or his engagement with the Company or in any way inconsistent
herewith, and Advisor will not during the Term hereof enter into or grant to anyone the same.

 

14.         Notices.
All notices and other communications hereunder shall be delivered or sent by registered or certified mail, return receipt requested,
addressed to the party at the address herein set forth, or to such other address as such party may designate in writing to the
other.

 

15.         Assignment.
This Agreement shall be binding upon and inure to the benefit of the parties and their respective legal representatives, successors
and permitted assigns. The Services to be rendered by Advisor are personal in nature. Adviser may not assign, delegate or transfer
this Agreement or any of his rights or obligations hereunder.

 

16.         Entire
Agreement; Waivers; Amendments. This Agreement constitutes the entire agreement between the parties as to the subject matter
hereof. No provision of this Agreement shall be waived, altered or canceled except in writing signed by the party against whom
such waiver, alteration or cancellation is asserted. The Company and Advisor agree that any amendment of this Agreement (including,
without limitation, any extension of its Term or any change in the consideration set forth above to be provided to Advisor hereunder)
or any other departure from the terms and conditions hereof must be signed by Advisor and an authorized representative of the Company.

 

17.         Governing
Law. This Agreement shall be governed by and construed in accordance with the internal laws of the Commonwealth of Massachusetts,
without regard to its body of law controlling conflict of laws.

 

18.         Enforcement.
Advisor agrees that this Agreement is enforceable through injunctive relief, specific performance or other equitable relief.
The invalidity or unenforceability of any provision hereof as to an obligation of a party shall in no way affect the validity or
enforceability of any other provision of this Agreement. Moreover, if one or more of the provisions contained in this Agreement
shall for any reason be held to be excessively broad as to scope, activity or subject so as to be unenforceable at law, such provision
or provisions shall be construed by limiting or reducing it or them, so as to be enforceable to the extent compatible with the
applicable law as it shall then appear.

 

    	7

    	 

    

  

19.         Miscellaneous

 

a.           The
Company may use Advisor’s name, and in doing so may cite the Advisor’s relationship with Employer, so long as any such
usage (i) is limited to reporting factual events or occurrences only, and (ii) is made in a manner that could not reasonably constitute
an endorsement of the Company or of any Company program, product or service.

 

b.           Advisor
and the Company acknowledge that (i) Advisor is entering into this Agreement in the Advisor’s individual capacity and not
as an employee or agent of the Employer, and (ii) Employer is not a party to this Agreement and has no liability or obligation
hereunder.

 

    	8

    	 

    

  

IN WITNESS WHEREOF,
the parties hereto have duly executed this Agreement as a sealed instrument as of the Effective Date.

 

	ENUMERAL BIOMEDICAL HOLDINGS, INC.	 	ADVISOR:
	 	 	 
	By:	/s/ Arthur H. Tinkelenberg	 	/s/ Barry Buckland
	 	 	 	 
	Name:	Arthur H. Tinkelenberg	 	Name: Barry Buckland

 

	Title:	President and CEO	 	Address:	 
	 	 	 	 
	Address:	One Kendall Square	 	 

 

	Building 400, Fourth Floor	 	 
	 	 	 
	Cambridge, MA 02139	 	 

 

	Attn:

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00237-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00237-of-00352.parquet"}]]